Page last updated: 2024-08-03 15:33:14

cp 466722

Description

2-(6,7-dimethoxy-4-quinazolinyl)-5-(2-pyridinyl)-1,2,4-triazol-3-amine : no description available [CHeBI]

Cross-References

ID Source	ID
PubMed CID	44551660
CHEMBL ID	2143829
SCHEMBL ID	15639218
CHEBI ID	91330
MeSH ID	M0525865

Synonyms (41)

Synonym
HY-11002
chembl2143829 ,
bdbm50145038
1080622-86-1
BCP9000544
CP-466722 ,
cp 466722
cp466722
HMS3265B19
HMS3265B20
HMS3265A20 ,
HMS3265A19
NCGC00263099-01
S2245
2-(6,7-dimethoxyquinazolin-4-yl)-5-(pyridin-2-yl)-2h-1,2,4-triazol-3-amine
1-(6,7-dimethoxy-4-quinazolinyl)-3-(2-pyridinyl)-1h-1,2,4-triazol-5-amine
BRD-K15592317-001-01-0
J-503445
2-(6,7-dimethoxy-quinazolin-4-yl)-5-pyridin-2-yl-2h-[1,2,4]triazol-3-ylamine
SCHEMBL15639218
gtpl9359
1-(6,7-dimethoxyquinazolin-4-yl)-3-(pyridin-2-yl)-1h-1,2,4-triazol-5-amine
AC-28457
2-(6,7-dimethoxyquinazolin-4-yl)-5-pyridin-2-yl-1,2,4-triazol-3-amine
DTXSID80659313
EX-A086
AKOS027422720
CHEBI:91330
cp466722, >=98% (hplc)
mfcd17392566
NCGC00263099-05
2-(6,7-dimethoxy-4-quinazolinyl)-5-(2-pyridinyl)-1,2,4-triazol-3-amine
Q27163212
BCP02229
SB19278
NCGC00263099-08
A25042
2-(6,7-dimethoxyquinazolin-4-yl)-5-(pyridin-2-yl)-2h-1,2,4-triazol-3-amine;cp-466722
NCGC00263099-02
AS-78299
Z2036684827

Drug Classes (1)

Class	Description
quinazolines	Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives.

Protein Targets (17)

Potency Measurements

Protein	Taxonomy	Measurement	Average (mM)	Bioassay(s)
PPM1D protein	Homo sapiens (human)	Potency	2.9411	AID1347411
cytochrome P450 family 3 subfamily A polypeptide 4	Homo sapiens (human)	Potency	23.9185	AID1645841
EWS/FLI fusion protein	Homo sapiens (human)	Potency	14.2231	AID1259252; AID1259253; AID1259255; AID1259256
G	Vesicular stomatitis virus	Potency	8.4866	AID1645842
cytochrome P450 2D6	Homo sapiens (human)	Potency	7.5637	AID1645840
tyrosine-protein kinase Yes	Homo sapiens (human)	Potency	2.7404	AID686947
Interferon beta	Homo sapiens (human)	Potency	4.3275	AID1347411; AID1645842
HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)	Potency	8.4866	AID1645842
Inositol hexakisphosphate kinase 1	Homo sapiens (human)	Potency	8.4866	AID1645842
cytochrome P450 2C9, partial	Homo sapiens (human)	Potency	8.4866	AID1645842

Inhibition Measurements

Protein	Taxonomy	Measurement	Average (mM)	Bioassay(s)
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)	IC50	1.4900	AID1635548
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)	IC50	5.4400	AID1635549
Serine/threonine-protein kinase mTOR	Homo sapiens (human)	IC50	4.5900	AID1635546
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)	IC50	1.0000	AID1635550
DNA-dependent protein kinase catalytic subunit	Homo sapiens (human)	IC50	0.8790	AID1635547
Serine-protein kinase ATM	Homo sapiens (human)	IC50	0.6748	AID1276244; AID1276306; AID1635523; AID1635524; AID1687210; AID1743714; AID1903635
Serine/threonine-protein kinase ATR	Homo sapiens (human)	IC50	30.0000	AID1635525

Bioassays (85)

Assay ID	Title	Year	Journal	Article
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 ISSN: 2472-5560	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5 ISSN: 1521-0111	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5 ISSN: 1521-0111	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347159	Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 ISSN: 1091-6490	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347160	Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 ISSN: 1091-6490	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173ISSN: 1872-9096	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID686947	qHTS for small molecule inhibitors of Yes1 kinase: Primary Screen	2013	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15 ISSN: 1464-3405	Identification of potent Yes1 kinase inhibitors using a library screening approach.
AID1745845	Primary qHTS for Inhibitors of ATXN expression	2022	The Journal of biological chemistry, 08, Volume: 298, Issue:8 ISSN: 1083-351X
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173ISSN: 1872-9096	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 ISSN: 1091-6490	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173ISSN: 1872-9096	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4 ISSN: 2211-1247	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1276260	Plasma protein binding in rat	2016	Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2 ISSN: 1520-4804	Optimization of a Novel Series of Ataxia-Telangiectasia Mutated Kinase Inhibitors as Potential Radiosensitizing Agents.
AID1276263	Stability of the compound in phosphate buffered saline assessed as compound stability time at pH 7.4 by UPLC-MS analysis	2016	Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2 ISSN: 1520-4804	Optimization of a Novel Series of Ataxia-Telangiectasia Mutated Kinase Inhibitors as Potential Radiosensitizing Agents.
AID1276267	Half life of the compound in aqueous buffer	2016	Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2 ISSN: 1520-4804	Optimization of a Novel Series of Ataxia-Telangiectasia Mutated Kinase Inhibitors as Potential Radiosensitizing Agents.
AID1276249	Half life in rat liver microsomes by UPLC-MS analysis	2016	Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2 ISSN: 1520-4804	Optimization of a Novel Series of Ataxia-Telangiectasia Mutated Kinase Inhibitors as Potential Radiosensitizing Agents.
AID1276271	Inhibition of ATM in human MCF7 cells assessed as inhibition of KAP1 phosphorylation at Ser824 residue preincubated for 30 mins followed cells exposed to 10 Gy irradiation measured after 1 hr by western blot analysis	2016	Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2 ISSN: 1520-4804	Optimization of a Novel Series of Ataxia-Telangiectasia Mutated Kinase Inhibitors as Potential Radiosensitizing Agents.
AID1276255	Intrinsic clearance in dog liver microsomes after 0.5 to 4 hrs by UPLC-MS analysis	2016	Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2 ISSN: 1520-4804	Optimization of a Novel Series of Ataxia-Telangiectasia Mutated Kinase Inhibitors as Potential Radiosensitizing Agents.
AID1276274	Sensitization of infrared-induced DNA damage in human MCF7 cells assessed as reduction in colony formation at 10 uM pretreated for 10 mins followed by irradiation for 4 hrs measured after 10 days by crystal violet staining analysis	2016	Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2 ISSN: 1520-4804	Optimization of a Novel Series of Ataxia-Telangiectasia Mutated Kinase Inhibitors as Potential Radiosensitizing Agents.
AID1276245	Solubility of the compound in PBS at pH 7.4 for 18 hrs by UV spectroscopic analysis	2016	Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2 ISSN: 1520-4804	Optimization of a Novel Series of Ataxia-Telangiectasia Mutated Kinase Inhibitors as Potential Radiosensitizing Agents.
AID1276250	Half life in human liver microsomes by UPLC-MS analysis	2016	Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2 ISSN: 1520-4804	Optimization of a Novel Series of Ataxia-Telangiectasia Mutated Kinase Inhibitors as Potential Radiosensitizing Agents.
AID1276252	Intrinsic clearance in CD-1 mouse liver microsomes after 0.5 to 4 hrs by UPLC-MS analysis	2016	Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2 ISSN: 1520-4804	Optimization of a Novel Series of Ataxia-Telangiectasia Mutated Kinase Inhibitors as Potential Radiosensitizing Agents.
AID1635523	Inhibition of ATM (unknown origin) using p53 as substrate incubated for 30 mins followed by substrate addition measured after 2 hrs in presence of ATP by HTRF method	2016	Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13 ISSN: 1520-4804	Discovery of Novel 3-Quinoline Carboxamides as Potent, Selective, and Orally Bioavailable Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase.
AID1276302	Half life in C57BL/6 mouse at 10 mg/kg, iv	2016	Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2 ISSN: 1520-4804	Optimization of a Novel Series of Ataxia-Telangiectasia Mutated Kinase Inhibitors as Potential Radiosensitizing Agents.
AID1903635	Competitive inhibition of ATM (unknown origin) measured by ATP-competitive binding assay	2022	European journal of medicinal chemistry, Apr-05, Volume: 233ISSN: 1768-3254	Discovery of novel ataxia telangiectasia mutated (ATM) kinase modulators: Computational simulation, biological evaluation and cancer combinational chemotherapy study.
AID1276265	Stability of the compound in phosphate buffered saline assessed as compound stability time at pH 3 by UPLC-MS analysis	2016	Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2 ISSN: 1520-4804	Optimization of a Novel Series of Ataxia-Telangiectasia Mutated Kinase Inhibitors as Potential Radiosensitizing Agents.
AID1276247	Permeability of the compound at 10 uM after 30 mins by PAMPA	2016	Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2 ISSN: 1520-4804	Optimization of a Novel Series of Ataxia-Telangiectasia Mutated Kinase Inhibitors as Potential Radiosensitizing Agents.
AID1276306	Inhibition of flag-tagged ATM (unknown origin) using p53 as substrate by ELISA	2016	Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2 ISSN: 1520-4804	Optimization of a Novel Series of Ataxia-Telangiectasia Mutated Kinase Inhibitors as Potential Radiosensitizing Agents.
AID1635525	Inhibition of ATR in human HT-29 cells assessed as reduction in Chk1 phosphorylation at Ser-345 residue after 60 mins in presence of 4-nitroquinoline-1-oxide by Hoechst 33258 staining based plate reader analysis	2016	Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13 ISSN: 1520-4804	Discovery of Novel 3-Quinoline Carboxamides as Potent, Selective, and Orally Bioavailable Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase.
AID1276246	Cytotoxicity against human BJ cells after 72 hrs by Cell Titer Glo assay	2016	Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2 ISSN: 1520-4804	Optimization of a Novel Series of Ataxia-Telangiectasia Mutated Kinase Inhibitors as Potential Radiosensitizing Agents.
AID1276254	Intrinsic clearance in human liver microsomes after 0.5 to 4 hrs by UPLC-MS analysis	2016	Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2 ISSN: 1520-4804	Optimization of a Novel Series of Ataxia-Telangiectasia Mutated Kinase Inhibitors as Potential Radiosensitizing Agents.
AID1276256	Stability in mouse plasma assessed as compound stability time by UPLC-MS analysis	2016	Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2 ISSN: 1520-4804	Optimization of a Novel Series of Ataxia-Telangiectasia Mutated Kinase Inhibitors as Potential Radiosensitizing Agents.
AID1743714	Inhibition of full length Flag-tagged ATM (unknown origin) using GST-p53(1 to 101 residues) as substrates incubated for 90 mins	2020	Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23 ISSN: 1520-4804	Synthetic Lethality through the Lens of Medicinal Chemistry.
AID1276262	Plasma protein binding in dog	2016	Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2 ISSN: 1520-4804	Optimization of a Novel Series of Ataxia-Telangiectasia Mutated Kinase Inhibitors as Potential Radiosensitizing Agents.
AID1276272	Inhibition of ATM in human MCF7 cells assessed as inhibition of p53 phosphorylation at Ser15 residue preincubated for 30 mins followed cells exposed to 10 Gy irradiation measured after 1 hr by western blot analysis	2016	Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2 ISSN: 1520-4804	Optimization of a Novel Series of Ataxia-Telangiectasia Mutated Kinase Inhibitors as Potential Radiosensitizing Agents.
AID1276295	Drug metabolism in C57BL/6 mouse assessed as 4-(5-amino-3-(pyridin-2-yl)-1H-1,2,4-triazol-1-yl)quinazoline-6,7,8-triol formation by qualitative tandem mass spectrometric analysis	2016	Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2 ISSN: 1520-4804	Optimization of a Novel Series of Ataxia-Telangiectasia Mutated Kinase Inhibitors as Potential Radiosensitizing Agents.
AID1687210	Inhibition of ATM in human MCF7 cells assessed as reduction in KAP1 phosphorylation	2019	Journal of medicinal chemistry, 03-28, Volume: 62, Issue:6 ISSN: 1520-4804	Optimization of Potent and Selective Ataxia Telangiectasia-Mutated Inhibitors Suitable for a Proof-of-Concept Study in Huntington's Disease Models.
AID1276261	Plasma protein binding in human	2016	Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2 ISSN: 1520-4804	Optimization of a Novel Series of Ataxia-Telangiectasia Mutated Kinase Inhibitors as Potential Radiosensitizing Agents.
AID1635549	Inhibition of human recombinant PI3Kbeta using PIP2/ATP as substrate incubated for 20 mins followed by substrate addition by Kinase Glo reagent based luminescence assay	2016	Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13 ISSN: 1520-4804	Discovery of Novel 3-Quinoline Carboxamides as Potent, Selective, and Orally Bioavailable Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase.
AID1635524	Inhibition of ATM phosphorylation at Ser-1981 residue in human HT-29 cells incubated for 1 hr followed by X-ray irradiation by Hoechst staining based fluorescence plate reader analysis	2016	Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13 ISSN: 1520-4804	Discovery of Novel 3-Quinoline Carboxamides as Potent, Selective, and Orally Bioavailable Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase.
AID1635550	Inhibition of human recombinant PI3Kgamma using PIP2/ATP as substrate incubated for 20 mins followed by substrate addition by Kinase Glo reagent based luminescence assay	2016	Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13 ISSN: 1520-4804	Discovery of Novel 3-Quinoline Carboxamides as Potent, Selective, and Orally Bioavailable Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase.
AID1276300	Toxicity in C57BL/6 mouse at 10 and 20 mg/kg, iv	2016	Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2 ISSN: 1520-4804	Optimization of a Novel Series of Ataxia-Telangiectasia Mutated Kinase Inhibitors as Potential Radiosensitizing Agents.
AID1276270	Inhibition of ATM in human MCF7 cells assessed as inhibition of enzyme phosphorylation at Ser1981 residue preincubated for 30 mins followed cells exposed to 10 Gy irradiation measured after 1 hr by western blot analysis	2016	Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2 ISSN: 1520-4804	Optimization of a Novel Series of Ataxia-Telangiectasia Mutated Kinase Inhibitors as Potential Radiosensitizing Agents.
AID1276257	Stability in rat plasma assessed as compound stability time by UPLC-MS analysis	2016	Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2 ISSN: 1520-4804	Optimization of a Novel Series of Ataxia-Telangiectasia Mutated Kinase Inhibitors as Potential Radiosensitizing Agents.
AID1276296	Drug metabolism in C57BL/6 mouse assessed as (2S,3S,4S,5R,6S)-6-(4-(5-amino-3-(pyridin-2-yl)-1H-1,2,4-triazol-1-yl)-7-methoxyquinazolin-6-yloxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid formation by qualitative tandem mass spectrometric analy	2016	Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2 ISSN: 1520-4804	Optimization of a Novel Series of Ataxia-Telangiectasia Mutated Kinase Inhibitors as Potential Radiosensitizing Agents.
AID1276244	Inhibition of ATM kinase in human MCF7 cells after 1 hr by immunofluorescence assay	2016	Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2 ISSN: 1520-4804	Optimization of a Novel Series of Ataxia-Telangiectasia Mutated Kinase Inhibitors as Potential Radiosensitizing Agents.
AID1635546	Inhibition of C-terminal FLAG-tagged recombinant mTOR (1362 to 2549 residues) (unknown origin) using Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2 as substrate after 90 mins by AlphaScreen assay	2016	Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13 ISSN: 1520-4804	Discovery of Novel 3-Quinoline Carboxamides as Potent, Selective, and Orally Bioavailable Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase.
AID1276251	Half life in dog liver microsomes by UPLC-MS analysis	2016	Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2 ISSN: 1520-4804	Optimization of a Novel Series of Ataxia-Telangiectasia Mutated Kinase Inhibitors as Potential Radiosensitizing Agents.
AID1635527	Intrinsic clearance in rat hepatocytes assessed per million cells measured up to 90 mins	2016	Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13 ISSN: 1520-4804	Discovery of Novel 3-Quinoline Carboxamides as Potent, Selective, and Orally Bioavailable Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase.
AID1635530	Buffer/octanol partition coefficient, log D of the compound at pH 7.4 by shake flask method	2016	Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13 ISSN: 1520-4804	Discovery of Novel 3-Quinoline Carboxamides as Potent, Selective, and Orally Bioavailable Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase.
AID1276292	Tmax in C57BL/6 mouse at 20 mg/kg, iv by UPLC-MS analysis	2016	Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2 ISSN: 1520-4804	Optimization of a Novel Series of Ataxia-Telangiectasia Mutated Kinase Inhibitors as Potential Radiosensitizing Agents.
AID1276301	Clearance in C57BL/6 mouse at 10 mg/kg, iv	2016	Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2 ISSN: 1520-4804	Optimization of a Novel Series of Ataxia-Telangiectasia Mutated Kinase Inhibitors as Potential Radiosensitizing Agents.
AID1276268	Cmax in C57BL/6 mouse at 20 mg/kg, iv by UPLC-MS analysis	2016	Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2 ISSN: 1520-4804	Optimization of a Novel Series of Ataxia-Telangiectasia Mutated Kinase Inhibitors as Potential Radiosensitizing Agents.
AID1276253	Intrinsic clearance in rat liver microsomes after 0.5 to 4 hrs by UPLC-MS analysis	2016	Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2 ISSN: 1520-4804	Optimization of a Novel Series of Ataxia-Telangiectasia Mutated Kinase Inhibitors as Potential Radiosensitizing Agents.
AID1276258	Plasma protein binding in mouse	2016	Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2 ISSN: 1520-4804	Optimization of a Novel Series of Ataxia-Telangiectasia Mutated Kinase Inhibitors as Potential Radiosensitizing Agents.
AID1276264	Stability of the compound in phosphate buffered saline assessed as compound stability time at pH 5 by UPLC-MS analysis	2016	Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2 ISSN: 1520-4804	Optimization of a Novel Series of Ataxia-Telangiectasia Mutated Kinase Inhibitors as Potential Radiosensitizing Agents.
AID1276293	Drug metabolism in C57BL/6 mouse assessed as 4-(5-amino-3-(pyridin-2-yl)-1H-1,2,4-triazol-1-yl)-7-methoxyquinazolin-6-ol formation by qualitative tandem mass spectrometric analysis	2016	Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2 ISSN: 1520-4804	Optimization of a Novel Series of Ataxia-Telangiectasia Mutated Kinase Inhibitors as Potential Radiosensitizing Agents.
AID1635547	Inhibition of DNAPK (unknown origin) using p53-based peptide substrate preincubated for 5 min prior to ATP addition	2016	Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13 ISSN: 1520-4804	Discovery of Novel 3-Quinoline Carboxamides as Potent, Selective, and Orally Bioavailable Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase.
AID1276248	Half life in CD-1 mouse liver microsomes by UPLC-MS analysis	2016	Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2 ISSN: 1520-4804	Optimization of a Novel Series of Ataxia-Telangiectasia Mutated Kinase Inhibitors as Potential Radiosensitizing Agents.
AID1276259	Stability in human plasma assessed as compound stability time by UPLC-MS analysis	2016	Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2 ISSN: 1520-4804	Optimization of a Novel Series of Ataxia-Telangiectasia Mutated Kinase Inhibitors as Potential Radiosensitizing Agents.
AID1635548	Inhibition of human recombinant PI3Kalpha using PIP2/ATP as substrate incubated for 20 mins followed by substrate addition by Kinase Glo reagent based luminescence assay	2016	Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13 ISSN: 1520-4804	Discovery of Novel 3-Quinoline Carboxamides as Potent, Selective, and Orally Bioavailable Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase.
AID1635526	Intrinsic clearance in human hepatocytes assessed per million cells measured up to 90 mins	2016	Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13 ISSN: 1520-4804	Discovery of Novel 3-Quinoline Carboxamides as Potent, Selective, and Orally Bioavailable Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7 ISSN: 1554-8937	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1794808	Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).	2014	Journal of biomolecular screening, Jul, Volume: 19, Issue:6 ISSN: 1552-454X	A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808	Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).	2022	Journal of enzyme inhibition and medicinal chemistry, Dec, Volume: 37, Issue:1 ISSN: 1475-6374
AID1345623	Human ATM serine/threonine kinase (Other PIKK family kinases)	2008	Cancer research, Sep-15, Volume: 68, Issue:18 ISSN: 1538-7445	Transient inhibition of ATM kinase is sufficient to enhance cellular sensitivity to ionizing radiation.

Research

Studies (17)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (5.88)	29.6817
2010's	7 (41.18)	24.3611
2020's	9 (52.94)	2.80

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (5.88%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	16 (94.12%)	84.16%

Substance	Classes	Roles	Relationship Strength
rtki cpd	aromatic ether; monochlorobenzenes; quinazolines	antineoplastic agent; antiviral agent; epidermal growth factor receptor antagonist; geroprotector	low
alfuzosin	monocarboxylic acid amide; quinazolines; tetrahydrofuranol	alpha-adrenergic antagonist; antihypertensive agent; antineoplastic agent	low
bunazosin	quinazolines		low
cgs 15943	aromatic amine; biaryl; furans; organochlorine compound; primary amino compound; quinazolines; triazoloquinazoline	adenosine A1 receptor antagonist; adenosine A2A receptor antagonist; antineoplastic agent; central nervous system stimulant	low
cl 387785	bromobenzenes; quinazolines; secondary carboxamide; ynamide	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; epidermal growth factor receptor antagonist	low
doxazosin	aromatic amine; benzodioxine; monocarboxylic acid amide; N-acylpiperazine; N-arylpiperazine; quinazolines	alpha-adrenergic antagonist; antihyperplasia drug; antihypertensive agent; antineoplastic agent; vasodilator agent	low
whi p97	quinazolines		low
ketanserin	aromatic ketone; organofluorine compound; piperidines; quinazolines	alpha-adrenergic antagonist; antihypertensive agent; cardiovascular drug; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; serotonergic antagonist	low
metolazone	organochlorine compound; quinazolines; sulfonamide	antihypertensive agent; diuretic; ion transport inhibitor	low
pd 153035	aromatic amine; aromatic ether; bromobenzenes; quinazolines; secondary amino compound	EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; epidermal growth factor receptor antagonist	low
pd168393	acrylamides; bromobenzenes; quinazolines; secondary carboxamide; substituted aniline	epidermal growth factor receptor antagonist	low
prazosin	aromatic ether; furans; monocarboxylic acid amide; piperazines; quinazolines	alpha-adrenergic antagonist; antihypertensive agent; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor	low
terazosin	furans; piperazines; primary amino compound; quinazolines	alpha-adrenergic antagonist; antihypertensive agent; antineoplastic agent	low
methaqualone	quinazolines	GABA agonist; sedative	low
quinethazone	quinazolines	antihypertensive agent; diuretic	low
quinazolines	azaarene; mancude organic heterobicyclic parent; ortho-fused heteroarene; quinazolines		low
mecloqualone	quinazolines		low
quinelorane	quinazolines		low
halofuginone	quinazolines		low
glycosine	quinazolines		low
febrifugine	quinazolines		low
2,3-trimethylene-4-quinazolone	quinazolines		low
fenquizone	quinazolines		low
fenazaquin	quinazolines	acaricide; mitochondrial NADH:ubiquinone reductase inhibitor	low
fluquinconazole	conazole fungicide; dichlorobenzene; organofluorine compound; quinazolines; triazole fungicide; triazoles	antifungal agrochemical; EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor	low
gefitinib	aromatic ether; monochlorobenzenes; monofluorobenzenes; morpholines; quinazolines; secondary amino compound; tertiary amino compound	antineoplastic agent; epidermal growth factor receptor antagonist	low
cyclazosin	aromatic amide; aromatic ether; furans; monocarboxylic acid amide; quinazolines; quinoxaline derivative	adenosine A2A receptor antagonist	low
glyantrypine	quinazolines		low
canertinib	monochlorobenzenes; morpholines; organofluorine compound; quinazolines	antineoplastic agent; tyrosine kinase inhibitor	low
erlotinib	aromatic ether; quinazolines; secondary amino compound; terminal acetylenic compound	antineoplastic agent; epidermal growth factor receptor antagonist; protein kinase inhibitor	low
lapatinib	furans; organochlorine compound; organofluorine compound; quinazolines	antineoplastic agent; tyrosine kinase inhibitor	low
(5-amino-3-triazolo[1,5-a]quinazolinyl)-(4-morpholinyl)methanone	quinazolines		low
mrs 1220	quinazolines		low
3-deoxyvasicine	quinazolines		low
N-benzylquinazolin-4-amine	benzenes; quinazolines; secondary amino compound		low
2-(4-hydroxy-3-methoxyphenyl)-3-(2-methoxyphenyl)-1,2-dihydroquinazolin-4-one	quinazolines		low
N-(cyclohexylmethyl)-5,6,7,8-tetrahydrotetrazolo[5,1-b]quinazolin-9-amine	quinazolines		low
N-(2-pyridinylmethyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[5,1-b]quinazolin-9-amine	quinazolines		low
N-[2-methyl-4-oxo-3-(phenylmethyl)-7-(1-piperidinyl)-6-quinazolinyl]-3-pyridinecarboxamide	quinazolines		low
N-(6-ethoxy-1,3-benzothiazol-2-yl)-2-[[3-(2-furanylmethyl)-4-oxo-2-quinazolinyl]thio]acetamide	quinazolines		low
2-pyridin-4-yl-2,3-dihydro-1H-quinazolin-4-one	quinazolines		low
N-[3-(trifluoromethyl)phenyl]-4-quinazolinamine	quinazolines		low
2-[(2-cyclohexyl-4-quinazolinyl)thio]-N-(4-methyl-1,2,5-oxadiazol-3-yl)acetamide	quinazolines		low
3-[[[[3-[(4-chlorophenyl)methyl]-2-methyl-4-oxo-6-quinazolinyl]amino]-oxomethyl]amino]propanoic acid ethyl ester	quinazolines		low
2-[[2-(3,4-dihydro-2H-quinolin-1-yl)-2-oxoethyl]thio]-3-ethyl-4-quinazolinone	quinazolines		low
2-[(3-ethyl-4-oxo-2-quinazolinyl)thio]acetic acid cyclohexyl ester	quinazolines		low
2-thiophen-2-yl-2,3-dihydro-1H-quinazolin-4-one	quinazolines		low
2-(pyridin-4-yl)-4-(pyrrolidin-1-yl)quinazoline	pyridines; pyrrolidines; quinazolines		low
5-methyl-6-pyridin-4-yl-6H-benzimidazolo[1,2-c]quinazoline	quinazolines		low
2-[[2-[(2-methoxy-2-oxoethyl)thio]-4-oxo-3-quinazolinyl]oxy]acetic acid methyl ester	quinazolines		low
2-(1,3-benzoxazol-2-ylamino)-5-spiro[1,6,7,8-tetrahydroquinazoline-4,1'-cyclopentane]one	quinazolines		low
3-methoxy-2-(3-pyridinylmethylthio)-4-quinazolinone	quinazolines		low
3,5,5-trimethyl-2-sulfanylidene-1,6-dihydrobenzo[h]quinazolin-4-one	quinazolines		low
N1-(6-bromo-4-quinazolinyl)-N4,N4-dimethylbenzene-1,4-diamine	quinazolines		low
N-(3-fluorophenyl)-2-(pyridin-4-yl)quinazolin-4-amine	aromatic amine; monofluorobenzenes; pyridines; quinazolines; secondary amino compound; substituted aniline		low
3-methyl-2-[2-(4-methyl-5-thiazolyl)ethylthio]-4-quinazolinone	quinazolines		low
N-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-(4-oxo-3-quinazolinyl)acetamide	quinazolines		low
6-bromo-3-phenyl-2-sulfanylidene-1H-quinazolin-4-one	quinazolines		low
N-methyl-2-(4-methylphenyl)-N-(1-methylpiperidin-4-yl)quinazolin-4-amine	piperidines; quinazolines; tertiary amino compound; toluenes		low
2-(2-furanyl)-3-(6-methyl-2-pyridinyl)-4-quinazolinone	quinazolines		low
2-(4-methoxyphenyl)-3-(3-pyridinyl)-4-quinazolinone	quinazolines		low
2-phenyl-1H-quinazoline-4-thione	quinazolines		low
2-(ethylthio)-[1,3,4]thiadiazolo[2,3-b]quinazolin-5-one	quinazolines		low
2-[(3-methyl-4-oxo-2-quinazolinyl)thio]-N-phenylacetamide	quinazolines		low
1,3-dimethyl-6-(4-morpholinylsulfonyl)quinazoline-2,4-dione	quinazolines		low
6,7-dimethoxy-3-phenyl-1H-quinazoline-2,4-dione	quinazolines		low
6-methoxy-4-methyl-2-[(2-methylphenyl)methylthio]quinazoline	quinazolines		low
2-(4-chlorophenyl)-4-propan-2-yloxyquinazoline	quinazolines		low
7-bromo-1,2,3,9-tetrahydropyrrolo[2,1-b]quinazoline	quinazolines		low
2-(3-methoxyphenyl)-4-propan-2-yloxyquinazoline	quinazolines		low
2-[[2-(5-methyl-2-thiophenyl)-2-oxoethyl]thio]-3-phenyl-4-quinazolinone	quinazolines		low
N-(phenylmethyl)-2-[[4-(trifluoromethyl)-5,6-dihydrobenzo[h]quinazolin-2-yl]thio]acetamide	quinazolines		low
2-(6-amino-2-methyl-4-oxo-3-quinazolinyl)-N-(2-methylphenyl)acetamide	quinazolines		low
6-amino-3-[(2-chlorophenyl)methyl]-2-propyl-4-quinazolinone	quinazolines		low
2-(4-chlorophenyl)-N-[2-(4-morpholinyl)ethyl]-4-quinazolinamine	quinazolines		low
4-(4-ethoxycarbonylanilino)-2-quinazolinecarboxylic acid ethyl ester	quinazolines		low
4-(4-anilinoanilino)-2-quinazolinecarboxylic acid ethyl ester	quinazolines		low
2-[[2-(3,4-dihydro-1H-isoquinolin-2-yl)-2-oxoethyl]thio]-3-phenyl-4-quinazolinone	quinazolines		low
N-(2,4-dimethoxyphenyl)-2-(1-pyrrolidinyl)-4-quinazolinamine	quinazolines		low
3-(4-oxo-3-quinazolinyl)-N-(4,5,6,7-tetrahydro-1,3-benzothiazol-2-yl)propanamide	quinazolines		low
4-methoxy-N-[2-[(4-nitrophenyl)methylthio]-4-oxo-3-quinazolinyl]benzamide	quinazolines		low
N-(4-methoxyphenyl)-2-(3-nitrophenyl)-4-quinazolinamine	quinazolines		low
2-[(2-tert-butyl-4-quinazolinyl)thio]-N-(4,5,6,7-tetrahydro-1,3-benzothiazol-2-yl)acetamide	quinazolines		low
1-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-[[2-(phenylmethyl)-4-quinazolinyl]thio]ethanone	quinazolines		low
2-[(2-propyl-4-quinazolinyl)thio]-N-(4,5,6,7-tetrahydro-1,3-benzothiazol-2-yl)acetamide	quinazolines		low
1-(3,4-dihydro-1H-isoquinolin-2-yl)-2-[(2-propyl-4-quinazolinyl)thio]ethanone	quinazolines		low
N-(5-methyl-3-isoxazolyl)-2-[(2-propan-2-yl-4-quinazolinyl)thio]acetamide	quinazolines		low
Src Inhibitor-1	aromatic ether; polyether; quinazolines; secondary amino compound	EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor	low
6,7-dimethoxy-N-[(4-methylphenyl)methyl]-4-quinazolinamine	quinazolines		low
9-methyl-5,6,7,8-tetrahydrotetrazolo[5,1-b]quinazoline	quinazolines		low
2-[(2,4-dichlorophenyl)methylthio]-6,7-dimethoxy-3-(thiophen-2-ylmethyl)-4-quinazolinimine	quinazolines		low
7-chloro-N-(2-furanylmethyl)-4-quinazolinamine	quinazolines		low
4-methoxy-N-(8-methyl-[1,3]dioxolo[4,5-g]quinazolin-6-yl)benzamide	quinazolines		low
SMER 28	organobromine compound; quinazolines; secondary amino compound	autophagy inducer	low
4-methoxy-2-(4-propoxyphenyl)quinazoline	quinazolines		low
2-butoxy-3-phenyl-4-quinazolinone	quinazolines		low
N,N-dibutyl-2-(pyridin-4-yl)quinazolin-4-amine	pyridines; quinazolines; tertiary amino compound		low
4-chloro-N-(8-methyl-[1,3]dioxolo[4,5-g]quinazolin-6-yl)benzamide	quinazolines		low
2-(2-bromophenyl)-5-[(7-nitro-4-quinazolinyl)oxymethyl]-1,3,4-oxadiazole	quinazolines		low
3-[[4-(2-benzofuranyl)-2-thiazolyl]methyl]-2-[(dimethylamino)methyl]-4-quinazolinone	quinazolines		low
3-(benzenesulfonyl)-N-(3-methylphenyl)-5-triazolo[1,5-a]quinazolinamine	quinazolines		low
4-[2-[[3-(4-methylphenyl)-5-triazolo[1,5-a]quinazolinyl]amino]ethyl]benzenesulfonamide	quinazolines		low
6-bromo-3-[4-nitro-3-(trifluoromethyl)phenyl]-2-propyl-4-quinazolinone	quinazolines		low
12-oxo-N-(4-phenyl-2-thiazolyl)-7,8,9,10-tetrahydro-6H-azepino[2,1-b]quinazoline-3-carboxamide	quinazolines		low
4,5-dimethyl-2-[[1-oxo-2-(4-quinazolinyloxy)ethyl]amino]-3-thiophenecarboxylic acid ethyl ester	quinazolines		low
7-[(6,8-dichloro-4-quinazolinyl)oxymethyl]-5-thiazolo[3,2-a]pyrimidinone	quinazolines		low
N-(2,3-dihydro-1H-inden-5-yl)-2-[[3-(2-fluorophenyl)-4-oxo-2-quinazolinyl]thio]acetamide	quinazolines		low
2-[[3-(2,4-difluorophenyl)-4-oxo-2-quinazolinyl]thio]-N-(2,3-dihydro-1H-inden-5-yl)acetamide	quinazolines		low
2-[[3-[(4-fluorophenyl)methyl]-4-oxo-2-quinazolinyl]thio]-N-(thiophen-2-ylmethyl)acetamide	quinazolines		low
3-(2-furanylmethyl)-4-oxo-N,N-dipropyl-2-sulfanylidene-1H-quinazoline-7-carboxamide	quinazolines		low
7-(4-quinazolinyloxymethyl)-5-thiazolo[3,2-a]pyrimidinone	quinazolines		low
N'-(4-quinazolinyl)acetohydrazide	quinazolines		low
4-methyl-N'-(4-quinazolinyl)benzohydrazide	quinazolines		low
N-{3-[(2-phenylquinazolin-4-yl)amino]phenyl}acetamide	acetamide; aromatic amine; quinazolines; secondary amino compound; substituted aniline		low
N-(2,3-dihydro-1H-inden-5-yl)-2-[(4-oxo-3-phenyl-2-quinazolinyl)thio]acetamide	quinazolines		low
2-[(3-butyl-4-oxo-2-quinazolinyl)thio]-N-cyclopropylacetamide	quinazolines		low
N4-(5-Fluoro-4-imino-3,4-dihydroquinazolin-3-yl)isonicotinamide	quinazolines		low
3-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-sulfanylidene-1H-quinazolin-4-one	quinazolines		low
2-[(4-chlorophenyl)methyl]-4-(prop-2-enylthio)quinazoline	quinazolines		low
2-(4-nitrophenyl)-N-(2-oxolanylmethyl)-4-quinazolinamine	quinazolines		low
7-chloro-2-methyl-3-(4-pyridylmethyl)-3,4-dihydroquinazolin-4-one	quinazolines		low
2-[(7-chloro-4-quinazolinyl)oxy]-1-(2,3-dihydro-1,4-benzodioxin-6-yl)ethanone	quinazolines		low
3,3-dimethyl-1-[[9-(methylthio)-5,6-dihydrothieno[3,4-h]quinazolin-2-yl]thio]-2-butanone	quinazolines		low
2-(4,6,7-Trimethyl-2-quinazolinyl)guanidine	quinazolines		low
LSM-19241	quinazolines		low
LSM-19663	quinazolines		low
N-[7-(2-furanyl)-5-oxo-7,8-dihydro-6H-quinazolin-2-yl]acetamide	quinazolines		low
2-(2,4-dichlorophenyl)-3-(phenylmethyl)-1,2-dihydroquinazolin-4-one	quinazolines		low
4-(3-methoxyphenyl)-3,4,5,6-tetrahydro-1H-benzo[h]quinazoline-2-thione	quinazolines		low
4-[[3-[2-(1-cyclohexenyl)ethyl]-4-oxo-2-sulfanylidene-1H-quinazolin-7-yl]-oxomethyl]-1-piperazinecarboxylic acid ethyl ester	quinazolines		low
2-(3-nitrophenyl)-N-(phenylmethyl)-4-quinazolinamine	quinazolines		low
3-(2-furanylmethyl)-2-phenyl-1,2-dihydroquinazolin-4-one	quinazolines		low
LSM-19894	quinazolines		low
importazole	quinazolines		low
2-(1,3-benzothiazol-2-ylamino)-5-spiro[1,6,7,8-tetrahydroquinazoline-4,1'-cyclopentane]one	quinazolines		low
6,7-dimethoxy-3-(2-oxolanylmethyl)-2-sulfanylidene-1H-quinazolin-4-one	quinazolines		low
4-(6-quinolinyl)-1,3,4,6,7,8-hexahydroquinazoline-2,5-dione	quinazolines		low
9-phenyl-1,5,6,7,8,9-hexahydro-[1,2,4]triazolo[5,1-b]quinazoline	quinazolines		low
2-[(3-butan-2-yl-4-oxo-2-quinazolinyl)thio]propanenitrile	quinazolines		low
altanserin	quinazolines		low
tandutinib	aromatic ether; N-arylpiperazine; N-carbamoylpiperazine; phenylureas; piperidines; quinazolines; tertiary amino compound	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor	low
zd 6474	aromatic ether; organobromine compound; organofluorine compound; piperidines; quinazolines; secondary amine	antineoplastic agent; tyrosine kinase inhibitor	low
N-[3,5-dimethyl-1-[(4-methylphenyl)methyl]-4-pyrazolyl]-2-[[4-(trifluoromethyl)-5,6-dihydrobenzo[h]quinazolin-2-yl]thio]acetamide	quinazolines		low
2-(methylthio)-6-phenyl-6,7-dihydro-5H-[1,2,4]triazolo[5,1-b]quinazolin-8-one	quinazolines		low
N'-[2-[(2-cyclohexyl-4-quinazolinyl)thio]-1-oxoethyl]-2-methylpropanehydrazide	quinazolines		low
1-(3,5-dimethyl-1-piperidinyl)-2-[[2-(thiophen-2-ylmethyl)-4-quinazolinyl]thio]ethanone	quinazolines		low
ml106	quinazolines		low
6-(1,3-benzodioxol-5-yl)-N-(2-furanylmethyl)-N-methyl-4-quinazolinamine	quinazolines		low
N-(2-furanylmethyl)-6-(3-methoxyphenyl)-N-methyl-4-quinazolinamine	quinazolines		low
6-(1,3-benzodioxol-5-yl)-N-[(3-methylphenyl)methyl]-4-quinazolinamine	quinazolines		low
6-(2-chlorophenyl)-N-(3-pyridinylmethyl)-4-quinazolinamine	quinazolines		low
6-(3-furanyl)-N-[(3-methylphenyl)methyl]-4-quinazolinamine	quinazolines		low
6-(3-pyridinyl)-N-(3-pyridinylmethyl)-4-quinazolinamine	quinazolines		low
6-(3-furanyl)-N-(thiophen-2-ylmethyl)-4-quinazolinamine	quinazolines		low
6-(3-methoxyphenyl)-N-(3-pyridinylmethyl)-4-quinazolinamine	quinazolines		low
6-(2-chlorophenyl)-N-(2-furanylmethyl)-N-methyl-4-quinazolinamine	quinazolines		low
6-(3-methoxyphenyl)-N-(thiophen-2-ylmethyl)-4-quinazolinamine	quinazolines		low
6-(3-furanyl)-N-(3-pyridinylmethyl)-4-quinazolinamine	quinazolines		low
N-[(3-methylphenyl)methyl]-6-(3-pyridinyl)-4-quinazolinamine	quinazolines		low
2-[5-[[2-(3-methoxypropylamino)-2-oxoethyl]thio]-3-oxo-2H-imidazo[1,2-c]quinazolin-2-yl]-N-(phenylmethyl)acetamide	quinazolines		low
3-[6-(1,4-dioxa-8-azaspiro[4.5]decan-8-yl)-6-oxohexyl]-2-sulfanylidene-1H-quinazolin-4-one	quinazolines		low
3-[2-[butyl(methyl)amino]ethyl]-6-(4-morpholinyl)-2-sulfanylidene-1H-quinazolin-4-one	quinazolines		low
N-(3-chlorophenyl)-2-[6,7-dimethoxy-2,4-dioxo-3-(2-oxolanylmethyl)-1-quinazolinyl]acetamide	quinazolines		low
2,4-dioxo-3-pentyl-N-[3-(1-piperidinyl)propyl]-1H-quinazoline-7-carboxamide	quinazolines		low
2-[(3-oxo-2-propan-2-yl-2H-imidazo[1,2-c]quinazolin-5-yl)thio]-N-[2-(4-sulfamoylphenyl)ethyl]acetamide	quinazolines		low
2-(6-benzimidazolo[1,2-c]quinazolinylthio)-N-(2-furanylmethyl)acetamide	quinazolines		low
2-(3-methylanilino)-[1,3,4]thiadiazolo[2,3-b]quinazolin-5-one	quinazolines		low
3-[4-(1,4-dioxa-8-azaspiro[4.5]decan-8-yl)-4-oxobutyl]-6,7-diethoxy-2-sulfanylidene-1H-quinazolin-4-one	quinazolines		low
5a,6,7,8,9,10-hexahydro-5H-azepino[2,1-b]quinazolin-12-one	quinazolines		low
N-(1,3-benzodioxol-5-ylmethyl)-3-cyclopentyl-2,4-dioxo-1H-quinazoline-7-carboxamide	quinazolines		low
6,7-diethoxy-3-[3-(2-oxo-1-pyrrolidinyl)propyl]-2-sulfanylidene-1H-quinazolin-4-one	quinazolines		low
2-(1,3-benzodioxol-5-yl)-3-hydroxy-1,2-dihydroquinazolin-4-one	quinazolines		low
5-(6,7-diethoxy-4-oxo-2-sulfanylidene-1H-quinazolin-3-yl)-N-(2-furanylmethyl)pentanamide	quinazolines		low
6-chloro-3-[2-(diethylamino)ethyl]-2-sulfanylidene-1H-quinazolin-4-one	quinazolines		low
2,4-dioxo-3-(2-oxolanylmethyl)-N-pentyl-1H-quinazoline-7-carboxamide	quinazolines		low
4-[1,3-dioxo-3-[(12-oxo-7,8,9,10-tetrahydro-6H-azepino[2,1-b]quinazolin-2-yl)amino]propyl]-1-piperazinecarboxylic acid ethyl ester	quinazolines		low
N-butyl-2-[[6-(4-morpholinyl)-4-oxo-3-(2-phenylethyl)-2-quinazolinyl]thio]acetamide	quinazolines		low
6,7-diethoxy-3-(3-methoxypropyl)-2-sulfanylidene-1H-quinazolin-4-one	quinazolines		low
savirin	quinazolines		low
4-[(6,7-diethoxy-2,4-dioxo-1H-quinazolin-3-yl)methyl]-N-(3-methoxypropyl)-1-cyclohexanecarboxamide	quinazolines		low
6,7-dimethoxy-4-(2-oxolanylmethylamino)-1H-quinazoline-2-thione	quinazolines		low
N-(5-methyl-1H-pyrazol-3-yl)-2-[[3-oxo-2-(phenylmethyl)-2H-imidazo[1,2-c]quinazolin-5-yl]thio]acetamide	quinazolines		low
3-(4-chlorophenyl)-2-(1-pyrrolidinyl)-4-quinazolinone	quinazolines		low
2-[2,4-dioxo-3-(phenylmethyl)-1-quinazolinyl]-N-(5-methyl-3-isoxazolyl)acetamide	quinazolines		low
2-(2-methylanilino)-[1,3,4]thiadiazolo[2,3-b]quinazolin-5-one	quinazolines		low
4-[4-oxo-2-[[2-oxo-2-[(phenylmethyl)amino]ethyl]thio]-3-quinazolinyl]-1-piperidinecarboxylic acid ethyl ester	quinazolines		low
3-hydroxy-2-(2-hydroxy-3-methoxyphenyl)-1,2-dihydroquinazolin-4-one	quinazolines		low
1-(12-oxo-7,8,9,10-tetrahydro-6H-azepino[2,1-b]quinazolin-2-yl)-3-(3-pyridinylmethyl)thiourea	quinazolines		low
3-[3-(N-ethylanilino)propyl]-6-(4-morpholinyl)-2-sulfanylidene-1H-quinazolin-4-one	quinazolines		low
8-methylene-7-(phenylmethyl)-5H-[1,3]dioxolo[4,5-g]quinazoline-6-thione	quinazolines		low
2-[4-methoxy-3-(4-morpholinylmethyl)phenyl]-3-(phenylmethyl)-1,2-dihydroquinazolin-4-one	quinazolines		low
N-(4-oxo-2-phenyl-1,2-dihydroquinazolin-3-yl)benzenesulfonamide	quinazolines		low
N-[2-[(3-nitrophenyl)methylthio]-4-oxo-3-quinazolinyl]benzamide	quinazolines		low
7-chloro-3-hydroxy-2-[3-(trifluoromethyl)phenyl]-4-quinazolinone	quinazolines		low
3,5-diethyl-2-(3-hydroxypropylamino)-5-methyl-6H-benzo[h]quinazolin-4-one	quinazolines		low
3-(2-methoxyphenyl)-2-methyl-4-oxo-1H-quinazoline-2-carboxylic acid methyl ester	quinazolines		low
1-butyl-1-methyl-3-(12-oxo-7,8,9,10-tetrahydro-6H-azepino[2,1-b]quinazolin-2-yl)thiourea	quinazolines		low
N,N-diethyl-2-[[7-[(4-methoxyphenyl)methyl]-8-oxo-[1,3]dioxolo[4,5-g]quinazolin-6-yl]thio]acetamide	quinazolines		low
6-(4-morpholinyl)-3-(2-phenylethyl)-2-sulfanylidene-1H-quinazolin-4-one	quinazolines		low
N-(1,3-benzodioxol-5-ylmethyl)-6-[6-(4-morpholinyl)-4-oxo-2-sulfanylidene-1H-quinazolin-3-yl]hexanamide	quinazolines		low
N-[4-oxo-2-(2-pyridinyl)-1,2-dihydroquinazolin-3-yl]acetamide	quinazolines		low
N-[3-(1-azepanylsulfonyl)-4-methylphenyl]-2-(4-quinazolinylthio)acetamide	quinazolines		low
3-(2-fluorophenyl)-4-oxo-2-sulfanylidene-1H-quinazoline-7-carboxylic acid methyl ester	quinazolines		low
2-(2-bromophenyl)-3-[3-(4-morpholinyl)propyl]-1,2-dihydroquinazolin-4-one	quinazolines		low
sch 79797	quinazolines		low
3,5-diethyl-2-(2-hydroxyethylamino)-5-methyl-6H-benzo[h]quinazolin-4-one	quinazolines		low
2-(2-(5-bromo-1h-indol-3-yl)ethyl)-3-(1-methylethoxyphenyl)-4-(3h)-quinazolinone	quinazolines		low
N-[2-[4-(dimethylamino)phenyl]-4-oxo-1,2-dihydroquinazolin-3-yl]carbamic acid ethyl ester	quinazolines		low
2-(4-morpholinyl)-10-pyridazino[6,1-b]quinazolinone	quinazolines		low
N-(4-ethylphenyl)-2-[[3-[3-(4-methyl-1-piperidinyl)propyl]-4-oxo-2-quinazolinyl]thio]acetamide	quinazolines		low
N-(3-{[2-(2-fluorophenyl)quinazolin-4-yl]amino}phenyl)acetamide	acetamide; aromatic amine; monofluorobenzenes; quinazolines; secondary amino compound; substituted aniline		low
1-cyclohexyl-3-(12-oxo-7,8,9,10-tetrahydro-6H-azepino[2,1-b]quinazolin-2-yl)thiourea	quinazolines		low
N-(2-methoxyethyl)-4-oxo-3-[3-(2-oxo-1-pyrrolidinyl)propyl]-2-sulfanylidene-1H-quinazoline-7-carboxamide	quinazolines		low
4-(4-propan-2-ylphenyl)-3,4,5,6-tetrahydro-1H-benzo[h]quinazolin-2-one	quinazolines		low
6-(6-bromo-4-oxo-2-sulfanylidene-1H-quinazolin-3-yl)-N-[2-(4-sulfamoylphenyl)ethyl]hexanamide	quinazolines		low
N-(3-methoxyphenyl)-2-[(4-oxo-3-propyl-2-quinazolinyl)thio]-2-phenylacetamide	quinazolines		low
2-thiophen-2-yl-N-(thiophen-2-ylmethyl)-4-quinazolinamine	quinazolines		low
N-(1-benzylpiperidin-4-yl)-2-(pyridin-3-yl)quinazolin-4-amine	aromatic amine; piperidines; pyridines; quinazolines; secondary amino compound; tertiary amino compound		low
2-(4-oxo-3-quinazolinyl)-N-[3-(1-piperidinylsulfonyl)phenyl]acetamide	quinazolines		low
N-[2-(4-methoxyphenyl)-4-oxo-1,2-dihydroquinazolin-3-yl]carbamic acid ethyl ester	quinazolines		low
7-chloro-3-[2-(1-cyclohexenyl)ethyl]-2-sulfanylidene-1H-quinazolin-4-one	quinazolines		low
4-[2-[[2-[(5-methyl-1H-pyrazol-3-yl)amino]-2-oxoethyl]thio]-4-oxo-3-quinazolinyl]-N-(phenylmethyl)butanamide	quinazolines		low
2-[[3-butyl-6-(4-morpholinyl)-4-oxo-2-quinazolinyl]thio]acetamide	quinazolines		low
4-(3,4-dimethoxyphenyl)-3,4,5,6-tetrahydro-1H-benzo[h]quinazoline-2-thione	quinazolines		low
2-[3-(1-benzotriazolylmethyl)-4-methoxyphenyl]-3-(4-methoxyphenyl)-1,2-dihydroquinazolin-4-one	quinazolines		low
N-cycloheptyl-3-(2-methoxyethyl)-2,4-dioxo-1H-quinazoline-7-carboxamide	quinazolines		low
cb676475	quinazolines		low
1,5-dioxo-2,4-dihydropyrrolo[1,2-a]quinazoline-3-carboxylic acid ethyl ester	quinazolines		low
GSK3-XIII	aromatic amine; pyrazoles; quinazolines; secondary amino compound	EC 2.7.11.26 (tau-protein kinase) inhibitor	low
2-(1,3-benzoxazol-2-ylamino)-7,7-dimethyl-4-(2-pyridinyl)-1,4,6,8-tetrahydroquinazolin-5-one	quinazolines		low
N-[2-(2-fluorophenyl)ethyl]-5,6,7,8-tetrahydro-[1,2,4]triazolo[5,1-b]quinazolin-9-amine	quinazolines		low
N-(1,3-benzodioxol-5-ylmethyl)-6-chloro-4-quinazolinamine	quinazolines		low
N-[3-(4-morpholinyl)propyl]-2,4-dioxo-3-(2-phenylethyl)-1H-quinazoline-7-carboxamide	quinazolines		low
3-(2-methoxyethyl)-2,4-dioxo-N-pentyl-1H-quinazoline-7-carboxamide	quinazolines		low
2-[(1-amino-1-oxopropan-2-yl)thio]-3-butyl-4-oxo-7-quinazolinecarboxylic acid methyl ester	quinazolines		low
ic 87114	6-aminopurines; biaryl; quinazolines	EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor	low
zm 447439	aromatic ether; benzamides; morpholines; polyether; quinazolines; secondary amino compound; tertiary amino compound	antineoplastic agent; apoptosis inducer; Aurora kinase inhibitor	low
linagliptin	aminopiperidine; quinazolines	EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor; hypoglycemic agent	low
bibw 2992	aromatic ether; enamide; furans; monochlorobenzenes; organofluorine compound; quinazolines; secondary carboxamide; tertiary amino compound	antineoplastic agent; tyrosine kinase inhibitor	low
sotrastaurin	indoles; maleimides; N-alkylpiperazine; N-arylpiperazine; quinazolines	anticoronaviral agent; EC 2.7.11.13 (protein kinase C) inhibitor; immunosuppressive agent	low
saracatinib	aromatic ether; benzodioxoles; diether; N-methylpiperazine; organochlorine compound; oxanes; quinazolines; secondary amino compound	anticoronaviral agent; antineoplastic agent; apoptosis inducer; autophagy inducer; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; radiosensitizing agent	low
luotonin a	quinazolines		low
PDGF receptor tyrosine kinase inhibitor III	aromatic ether; N-arylpiperazine; N-carbamoylpiperazine; phenylureas; quinazolines; tertiary amino compound	EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor	low
erastin	aromatic ether; diether; monochlorobenzenes; N-acylpiperazine; N-alkylpiperazine; quinazolines; tertiary carboxamide	antineoplastic agent; ferroptosis inducer; voltage-dependent anion channel inhibitor	low
azd 8931	aromatic ether; monochlorobenzenes; monofluorobenzenes; piperidines; quinazolines; secondary amino compound; tertiary amino compound	EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; epidermal growth factor receptor antagonist	low
azd 1152	anilide; monoalkyl phosphate; monofluorobenzenes; pyrazoles; quinazolines; secondary amino compound; secondary carboxamide; tertiary amino compound	antineoplastic agent; Aurora kinase inhibitor; prodrug	low
pf 00299804	enamide; monochlorobenzenes; monofluorobenzenes; piperidines; quinazolines; secondary amino compound; secondary carboxamide; tertiary amino compound	antineoplastic agent; epidermal growth factor receptor antagonist	low
lapatinib ditosylate	quinazolines		low
idelalisib	aromatic amine; organofluorine compound; purines; quinazolines; secondary amino compound	antineoplastic agent; apoptosis inducer; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor	low
N-(2-methoxyethyl)-2-[[3-[(4-methoxyphenyl)methyl]-6-(4-morpholinyl)-4-oxo-2-quinazolinyl]thio]acetamide	quinazolines		low
4-[(2-methyl-[1,2,4]triazolo[1,5-c]quinazolin-5-yl)hydrazo]-4-oxo-N-propan-2-ylbutanamide	quinazolines		low
N-butyl-N-methyl-4-[(2-methyl-[1,2,4]triazolo[1,5-c]quinazolin-5-yl)hydrazo]-4-oxobutanamide	quinazolines		low
2-[4-[1-[(2-fluorophenyl)methyl]-2,4-dioxo-3-quinazolinyl]phenyl]-N-(2-oxolanylmethyl)acetamide	quinazolines		low
2-[6,7-dimethoxy-3-(3-methoxyphenyl)-2,4-dioxo-1-quinazolinyl]-N-(5-methyl-1H-pyrazol-3-yl)acetamide	quinazolines		low
N-butyl-3-[1-[(2,5-dimethylphenyl)methyl]-2,4-dioxo-3-quinazolinyl]propanamide	quinazolines		low
1-[(4-methylphenyl)methyl]-2,4-dioxo-N-(phenylmethyl)-3-prop-2-enyl-7-quinazolinecarboxamide	quinazolines		low
3-[(4-methoxyphenyl)methyl]-N-(3-methoxypropyl)-2,4-dioxo-1H-quinazoline-7-carboxamide	quinazolines		low
2-[1-(4-bromophenoxy)butyl]-8,9-dimethoxy-3H-[1,2,4]triazolo[1,5-c]quinazoline-5-thione	quinazolines		low
azd 1152-hqpa	anilide; monofluorobenzenes; primary alcohol; pyrazoles; quinazolines; secondary amino compound; secondary carboxamide; tertiary amino compound	antineoplastic agent; Aurora kinase inhibitor	low
N-[3-(diethylamino)propyl]-4-[(2-methyl-[1,2,4]triazolo[1,5-c]quinazolin-5-yl)hydrazo]-4-oxobutanamide	quinazolines		low
N-(3-ethynylphenyl)-6,7-dimethoxy-4-quinazolinamine	quinazolines		low
chaetominine	indole alkaloid; lactam; organic heterotetracyclic compound; quinazolines	metabolite	low
N-[3-(1-azepanyl)propyl]-3-[(4-methoxyphenyl)methyl]-2,4-dioxo-1H-quinazoline-7-carboxamide	quinazolines		low
2-[[6-(4-morpholinyl)-4-oxo-3-(2-phenylethyl)-2-quinazolinyl]thio]-N-(2-oxolanylmethyl)acetamide	quinazolines		low
2-[[2-[2-(1-piperidinyl)ethyl]-[1,2,4]triazolo[1,5-c]quinazolin-5-yl]thio]-N-[2-(4-sulfamoylphenyl)ethyl]acetamide	quinazolines		low
3-(4-methylphenyl)-5-oxo-N-propyl-8-thiazolo[2,3-b]quinazolinecarboxamide	quinazolines		low
3-(4-methylphenyl)-5-oxo-8-thiazolo[2,3-b]quinazolinecarboxamide	quinazolines		low
zm323881	aromatic ether; benzyl ether; fluorophenol; halophenol; monofluorobenzenes; organic cation; quinazolines; secondary amino compound; substituted aniline	vascular endothelial growth factor receptor antagonist	low
6-(3,5-dimethyl-4-isoxazolyl)-N-[(3-methoxyphenyl)methyl]-4-quinazolinamine	quinazolines		low
6-(3,5-dimethyl-4-isoxazolyl)-N-[(2-ethoxyphenyl)methyl]-4-quinazolinamine	quinazolines		low
N-[4-[[[6-(3,5-dimethyl-4-isoxazolyl)-4-quinazolinyl]amino]methyl]phenyl]acetamide	quinazolines		low
6-(3,5-dimethyl-4-isoxazolyl)-N-[(1-methyl-2-piperidinyl)methyl]-4-quinazolinamine	quinazolines		low
6-(3,5-dimethyl-4-isoxazolyl)-N-[1-(2-furanyl)ethyl]-4-quinazolinamine	quinazolines		low
6-(3,5-dimethyl-4-isoxazolyl)-N-[(3-methyl-2-thiophenyl)methyl]-4-quinazolinamine	quinazolines		low
4-[2-[(6-chloro-4-quinazolinyl)amino]ethyl]phenol	quinazolines		low
ast 1306	quinazolines		low
2-[[2-(phenoxymethyl)-4-quinazolinyl]thio]acetic acid methyl ester	quinazolines		low
poziotinib	acrylamides; aromatic ether; dichlorobenzene; diether; monofluorobenzenes; N-acylpiperidine; quinazolines; secondary amino compound; substituted aniline	antineoplastic agent; apoptosis inducer; epidermal growth factor receptor antagonist	low
N-[4-[[5-[5-hydroxy-4-oxo-3-(phenylmethyl)-1,2-dihydroquinazolin-2-yl]-2-methoxyphenyl]methoxy]phenyl]acetamide	quinazolines		low
N-(2-furanylmethyl)-N-methyl-6-(1-methyl-5-indolyl)-4-quinazolinamine	quinazolines		low
6-(2-chlorophenyl)-N-[(3-methylphenyl)methyl]-4-quinazolinamine	quinazolines		low
6-(3-methoxyphenyl)-N-[(3-methylphenyl)methyl]-4-quinazolinamine	quinazolines		low
6-(2,3-dihydro-1,4-benzodioxin-6-yl)-N-[(3-methylphenyl)methyl]-4-quinazolinamine	quinazolines		low
6-(2-chlorophenyl)-N-(thiophen-2-ylmethyl)-4-quinazolinamine	quinazolines		low
6-(3-chlorophenyl)-N-(thiophen-2-ylmethyl)-4-quinazolinamine	quinazolines		low
6-(3-pyridinyl)-N-(thiophen-2-ylmethyl)-4-quinazolinamine	quinazolines		low
6-(3-methylphenyl)-N-(thiophen-2-ylmethyl)-4-quinazolinamine	quinazolines		low
6-(1-methyl-5-indolyl)-N-(thiophen-2-ylmethyl)-4-quinazolinamine	quinazolines		low
6-(2,3-dihydro-1,4-benzodioxin-6-yl)-N-(thiophen-2-ylmethyl)-4-quinazolinamine	quinazolines		low
N-(1,3-benzodioxol-5-ylmethyl)-6-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-quinazolinamine	quinazolines		low
6-(2,3-dihydro-1,4-benzodioxin-6-yl)-N-(3-pyridinylmethyl)-4-quinazolinamine	quinazolines		low
6-(1,3-benzodioxol-5-yl)-N-[(3-fluorophenyl)methyl]-4-quinazolinamine	quinazolines		low
6-(3-chlorophenyl)-N-(3-pyridinylmethyl)-4-quinazolinamine	quinazolines		low
6-(3-methylphenyl)-N-(3-pyridinylmethyl)-4-quinazolinamine	quinazolines		low
6-(1,3-benzodioxol-5-yl)-N-(3-pyridinylmethyl)-4-quinazolinamine	quinazolines		low
N-(1,3-benzodioxol-5-ylmethyl)-6-(2-chlorophenyl)-4-quinazolinamine	quinazolines		low
N-(1,3-benzodioxol-5-ylmethyl)-6-(3-methoxyphenyl)-4-quinazolinamine	quinazolines		low
N-(1,3-benzodioxol-5-ylmethyl)-6-(3-pyridinyl)-4-quinazolinamine	quinazolines		low
N-(1,3-benzodioxol-5-ylmethyl)-6-(3-furanyl)-4-quinazolinamine	quinazolines		low
6-(2-chlorophenyl)-N-[(4-methyl-2-thiophenyl)methyl]-4-quinazolinamine	quinazolines		low
6-(3-chlorophenyl)-N-[(4-methyl-2-thiophenyl)methyl]-4-quinazolinamine	quinazolines		low
6-(3-methoxyphenyl)-N-[(4-methyl-2-thiophenyl)methyl]-4-quinazolinamine	quinazolines		low
N-[(4-methyl-2-thiophenyl)methyl]-6-(3-pyridinyl)-4-quinazolinamine	quinazolines		low
6-(1,3-benzodioxol-5-yl)-N-[(4-methyl-2-thiophenyl)methyl]-4-quinazolinamine	quinazolines		low
6-(2,3-dihydro-1,4-benzodioxin-6-yl)-N-[(4-methyl-2-thiophenyl)methyl]-4-quinazolinamine	quinazolines		low
6-(3-furanyl)-N-[(4-methyl-2-thiophenyl)methyl]-4-quinazolinamine	quinazolines		low
4-[5-(3-hydroxy-4-oxo-1,2-dihydroquinazolin-2-yl)-2-furanyl]benzonitrile	quinazolines		low
2-[5-(2-fluorophenyl)-2-furanyl]-3-hydroxy-1,2-dihydroquinazolin-4-one	quinazolines		low
3-hydroxy-2-(5-thiophen-2-yl-2-furanyl)-1,2-dihydroquinazolin-4-one	quinazolines		low
2-[5-(3-fluorophenyl)-2-furanyl]-3-hydroxy-1,2-dihydroquinazolin-4-one	quinazolines		low
3-hydroxy-2-[5-[4-(trifluoromethyl)phenyl]-2-furanyl]-1,2-dihydroquinazolin-4-one	quinazolines		low
6-(1,3-benzodioxol-5-yl)-N-methyl-N-(thiophen-2-ylmethyl)-4-quinazolinamine	quinazolines		low
[5-[4-[(5-methyl-2-furanyl)methylamino]-6-quinazolinyl]-2-furanyl]methanol	quinazolines		low
unc 0638	quinazolines		low
unc 0321	quinazolines		low
ML240	aromatic amine; aromatic ether; benzimidazoles; primary amino compound; quinazolines; secondary amino compound	antineoplastic agent	low
ncgc00242364	quinazolines		low
2-methoxy-N-[3-[4-[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]anilino]-6-quinazolinyl]prop-2-enyl]acetamide	aromatic ether; methylpyridines; olefinic compound; quinazolines; secondary amino compound; secondary carboxamide; toluenes		low
N-[4-(3-chloro-4-fluoroanilino)-7-[[(3S)-3-oxolanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-butenamide	quinazolines		low
N-[4-(3-chloro-4-fluoroanilino)-7-methoxy-6-quinazolinyl]-4-(1-piperidinyl)-2-butenamide	quinazolines		low
2-methoxy-n-(3-methyl-2-oxo-1,2,3,4-tetrahydroquinazolin-6-yl)benzenesulfonamide	quinazolines		low
nu 1025	phenols; quinazolines	EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor	low
1-[amino-[(6-methoxy-4-methyl-2-quinazolinyl)amino]methylidene]-3-phenylurea	quinazolines		low
4-oxo-2-(trifluoromethyl)-1H-quinazoline-6-carboxylic acid ethyl ester	quinazolines		low
4-hydroxyquinazoline	quinazolines		low
2-(3,4-dihydro-1H-isoquinolin-2-ylmethyl)-1H-quinazolin-4-one	quinazolines		low
2-[(2-methyl-2,3-dihydroindol-1-yl)methyl]-4-oxo-1H-quinazoline-7-carboxylic acid methyl ester	quinazolines		low
2-[[[5,7-bis(ethylamino)-[1,2,4]triazolo[4,3-a][1,3,5]triazin-3-yl]thio]methyl]-1H-quinazolin-4-one	quinazolines		low
3-(4-oxo-1H-quinazolin-2-yl)propanoic acid (3,5-dimethyl-4-isoxazolyl)methyl ester	quinazolines		low
N-(1,3-benzodioxol-5-ylmethyl)-3-methoxy-N-[(4-oxo-1H-quinazolin-2-yl)methyl]benzamide	quinazolines		low
1-cyclopentyl-1-[(4-oxo-1H-quinazolin-2-yl)methyl]-3-(phenylmethyl)urea	quinazolines		low
6,8-dibromo-2-[[[4-(difluoromethoxy)phenyl]methyl-methylamino]methyl]-1H-quinazolin-4-one	quinazolines		low
2-(5'-chloro-2'-phosphoryloxyphenyl)-6-chloro-4-(3h)-quinazolinone	aryl phosphate; monochlorobenzenes; quinazolines	fluorochrome	low
glycosminine	quinazolines		low
N-[(4-oxo-1H-quinazolin-2-yl)methyl]-N-(2-phenylethyl)butanamide	quinazolines		low
2-(4-methoxyphenyl)-1H-quinazolin-4-one	quinazolines		low
2-[(7-methoxy-4-methyl-2-quinazolinyl)amino]-5,6-dimethyl-1H-pyrimidin-4-one	quinazolines		low
6,7-dimethoxy-2-[(1H-1,2,4-triazol-5-ylthio)methyl]-1H-quinazolin-4-one	quinazolines		low
2-[(dimethylamino)methyl]-4-spiro[1,6-dihydrobenzo[h]quinazoline-5,1'-cyclohexane]one	quinazolines		low
2-(diethylaminomethyl)-4-spiro[1,6-dihydrobenzo[h]quinazoline-5,1'-cyclohexane]one	quinazolines		low
2-[5-(3-chlorophenyl)-2-furanyl]-1H-quinazolin-4-one	quinazolines		low
2-[(6-ethyl-4-methyl-2-quinazolinyl)amino]-1H-quinazolin-4-one	quinazolines		low
2-[(2-pyridinylthio)methyl]-1H-quinazolin-4-one	quinazolines		low
5,5-diethyl-2-(2-hydroxyethylamino)-1,6-dihydrobenzo[h]quinazolin-4-one	quinazolines		low
1-[(7-chloro-4-oxo-1H-quinazolin-2-yl)methyl]-4-piperidinecarboxamide	quinazolines		low
3-ethyl-2-[(4-oxo-1H-quinazolin-2-yl)methylthio]-4-quinazolinone	quinazolines		low
6,7-dimethoxy-2-[[methyl-[(4-oxo-1H-quinazolin-2-yl)methyl]amino]methyl]-1H-quinazolin-4-one	quinazolines		low
2-[(6-ethyl-4-methyl-2-quinazolinyl)amino]-6-(methoxymethyl)-1H-pyrimidin-4-one	quinazolines		low
5,5-diethyl-2-hydrazinyl-1,6-dihydrobenzo[h]quinazolin-4-one	quinazolines		low
3-(3-ethoxypropyl)-1-[(4-oxo-1H-quinazolin-2-yl)methyl]-1-(phenylmethyl)thiourea	quinazolines		low
chrysogine	cyclic amide; quinazoline alkaloid; quinazolines; secondary alcohol; secondary amide	Aspergillus metabolite; biological pigment; marine metabolite	low
N-[(cyclohexylamino)-oxomethyl]-2-[ethyl-[(4-oxo-1H-quinazolin-2-yl)methyl]amino]acetamide	quinazolines		low
7-[[ethyl-[(4-oxo-1H-quinazolin-2-yl)methyl]amino]methyl]-5-thiazolo[3,2-a]pyrimidinone	quinazolines		low
2-[[(6-ethyl-4-oxo-3-prop-2-enyl-2-thieno[2,3-d]pyrimidinyl)thio]methyl]-4-oxo-1H-quinazoline-7-carboxylic acid methyl ester	quinazolines		low
ARS-1620	quinazolines	antineoplastic agent; antiviral agent; inhibitor	low

Substance	Studies	Classes	Roles	First Year	Last Year	Average Age	Relationship Strength	2010's	post-2020
pk 11195	1	aromatic amide; isoquinolines; monocarboxylic acid amide; monochlorobenzenes	antineoplastic agent	2013	2013	11.0	low	1	0
pd 173074	1	aromatic amine; biaryl; dimethoxybenzene; pyridopyrimidine; tertiary amino compound; ureas	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; fibroblast growth factor receptor antagonist	2013	2013	11.0	low	1	0
abt 702	1	bipyridines		2013	2013	11.0	low	1	0
aurintricarboxylic acid	1	monohydroxybenzoic acid; quinomethanes; tricarboxylic acid	fluorochrome; histological dye; insulin-like growth factor receptor 1 antagonist	2020	2020	4.0	low	1	0
bicalutamide	1	(trifluoromethyl)benzenes; monocarboxylic acid amide; monofluorobenzenes; nitrile; sulfone; tertiary alcohol		2013	2013	11.0	low	1	0
verapamil	1	aromatic ether; nitrile; polyether; tertiary amino compound		2013	2013	11.0	low	1	0
celecoxib	1	organofluorine compound; pyrazoles; sulfonamide; toluenes	cyclooxygenase 2 inhibitor; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug	2013	2013	11.0	low	1	0
chelerythrine	1	benzophenanthridine alkaloid; organic cation	antibacterial agent; antineoplastic agent; EC 2.7.11.13 (protein kinase C) inhibitor	2013	2013	11.0	low	1	0
chloroquine	1	aminoquinoline; organochlorine compound; secondary amino compound; tertiary amino compound	anticoronaviral agent; antimalarial; antirheumatic drug; autophagy inhibitor; dermatologic drug	2022	2022	2.0	low	0	1
furosemide	1	chlorobenzoic acid; furans; sulfonamide	environmental contaminant; loop diuretic; xenobiotic	2013	2013	11.0	low	1	0
gossypol	2			2013	2020	7.5	low	2	0
fasudil	1	isoquinolines; N-sulfonyldiazepane	antihypertensive agent; calcium channel blocker; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; geroprotector; neuroprotective agent; nootropic agent; vasodilator agent	2013	2013	11.0	low	1	0
indirubin-3'-monoxime	1			2013	2013	11.0	low	1	0
leflunomide	1	(trifluoromethyl)benzenes; isoxazoles; monocarboxylic acid amide	antineoplastic agent; antiparasitic agent; EC 1.3.98.1 [dihydroorotate oxidase (fumarate)] inhibitor; EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; hepatotoxic agent; immunosuppressive agent; non-steroidal anti-inflammatory drug; prodrug; pyrimidine synthesis inhibitor; tyrosine kinase inhibitor	2013	2013	11.0	low	1	0
letrozole	1	nitrile; triazoles	antineoplastic agent; EC 1.14.14.14 (aromatase) inhibitor	2013	2013	11.0	low	1	0
lg 100268	1			2013	2013	11.0	low	1	0
2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one	1	chromones; morpholines; organochlorine compound	autophagy inhibitor; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; geroprotector	2020	2020	4.0	low	1	0
metformin	1	guanidines	environmental contaminant; geroprotector; hypoglycemic agent; xenobiotic	2013	2013	11.0	low	1	0
mitoxantrone	1	dihydroxyanthraquinone	analgesic; antineoplastic agent	2013	2013	11.0	low	1	0
entinostat	1	benzamides; carbamate ester; primary amino compound; pyridines; substituted aniline	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor	2013	2013	11.0	low	1	0
olprinone	1	bipyridines		2013	2013	11.0	low	1	0
omeprazole	1	aromatic ether; benzimidazoles; pyridines; sulfoxide		2013	2013	11.0	low	1	0
pioglitazone	1	aromatic ether; pyridines; thiazolidinediones	antidepressant; cardioprotective agent; EC 2.7.1.33 (pantothenate kinase) inhibitor; EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; geroprotector; hypoglycemic agent; insulin-sensitizing drug; PPARgamma agonist; xenobiotic	2013	2013	11.0	low	1	0
3-[(3,5-dibromo-4-hydroxyphenyl)methylidene]-5-iodo-1H-indol-2-one	1	indoles		2013	2013	11.0	low	1	0
riluzole	1	benzothiazoles		2013	2013	11.0	low	1	0
sb 206553	1	pyrroloindole		2013	2013	11.0	low	1	0
sb 220025	1	aminopyrimidine; imidazoles; organofluorine compound; piperidines	angiogenesis inhibitor; anti-inflammatory agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor	2013	2013	11.0	low	1	0
sb 202190	1	imidazoles; organofluorine compound; phenols; pyridines	apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor	2013	2013	11.0	low	1	0
sk&f 86002	1	imidazoles		2013	2013	11.0	low	1	0
imatinib	1	aromatic amine; benzamides; N-methylpiperazine; pyridines; pyrimidines	antineoplastic agent; apoptosis inducer; tyrosine kinase inhibitor	2013	2013	11.0	low	1	0
vorinostat	1	dicarboxylic acid diamide; hydroxamic acid	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor	2013	2013	11.0	low	1	0
sulfasalazine	1			2013	2013	11.0	low	1	0
2-[4-(1,2-diphenylbut-1-enyl)phenoxy]-N,N-dimethylethanamine	1	stilbenoid		2013	2013	11.0	low	1	0
troglitazone	1	chromanes; thiazolidinone	anticoagulant; anticonvulsant; antineoplastic agent; antioxidant; EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; hypoglycemic agent; platelet aggregation inhibitor; vasodilator agent	2013	2013	11.0	low	1	0
azacitidine	1	N-glycosyl-1,3,5-triazine; nucleoside analogue	antineoplastic agent	2013	2013	11.0	low	1	0
podophyllotoxin	1	furonaphthodioxole; lignan; organic heterotetracyclic compound	antimitotic; antineoplastic agent; keratolytic drug; microtubule-destabilising agent; plant metabolite; tubulin modulator	2013	2013	11.0	low	1	0
formestane	1	17-oxo steroid; 3-oxo-Delta(4) steroid; enol; hydroxy steroid	antineoplastic agent; EC 1.14.14.14 (aromatase) inhibitor	2013	2013	11.0	low	1	0
hydroxychloroquine sulfate	1			2013	2013	11.0	low	1	0
amiloride hydrochloride, anhydrous	1	hydrochloride	diuretic; sodium channel blocker	2013	2013	11.0	low	1	0
acadesine	1	1-ribosylimidazolecarboxamide; aminoimidazole; nucleoside analogue	antineoplastic agent; platelet aggregation inhibitor	2013	2013	11.0	low	1	0
cladribine	1	organochlorine compound; purine 2'-deoxyribonucleoside	antineoplastic agent; immunosuppressive agent	2013	2013	11.0	low	1	0
zidovudine	1	azide; pyrimidine 2',3'-dideoxyribonucleoside	antimetabolite; antiviral drug; HIV-1 reverse transcriptase inhibitor	2013	2013	11.0	low	1	0
etoposide	1	beta-D-glucoside; furonaphthodioxole; organic heterotetracyclic compound	antineoplastic agent; DNA synthesis inhibitor	2022	2022	2.0	low	0	1
lonidamine	1	dichlorobenzene; indazoles; monocarboxylic acid	antineoplastic agent; antispermatogenic agent; EC 2.7.1.1 (hexokinase) inhibitor; geroprotector	2013	2013	11.0	low	1	0
simvastatin	1	delta-lactone; fatty acid ester; hexahydronaphthalenes; statin (semi-synthetic)	EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor; EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor; ferroptosis inducer; geroprotector; prodrug	2013	2013	11.0	low	1	0
itraconazole	1	aromatic ether; conazole antifungal drug; cyclic ketal; dichlorobenzene; dioxolane; N-arylpiperazine; triazole antifungal drug; triazoles	EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor; Hedgehog signaling pathway inhibitor; P450 inhibitor	2013	2013	11.0	low	1	0
pravadoline	1			2013	2013	11.0	low	1	0
zileuton	1	1-benzothiophenes; ureas	anti-asthmatic drug; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; ferroptosis inhibitor; leukotriene antagonist; non-steroidal anti-inflammatory drug	2013	2013	11.0	low	1	0
niguldipine	1	diarylmethane		2013	2013	11.0	low	1	0
topotecan	1	pyranoindolizinoquinoline	antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor	2013	2013	11.0	low	1	0
eliprodil	1	monochlorobenzenes; monofluorobenzenes; piperidines; secondary alcohol; tertiary amino compound		2013	2013	11.0	low	1	0
gemcitabine	1	organofluorine compound; pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent; antiviral drug; DNA synthesis inhibitor; EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor; environmental contaminant; immunosuppressive agent; photosensitizing agent; prodrug; radiosensitizing agent; xenobiotic	2013	2013	11.0	low	1	0
irinotecan	2	carbamate ester; delta-lactone; N-acylpiperidine; pyranoindolizinoquinoline; ring assembly; tertiary alcohol; tertiary amino compound	antineoplastic agent; apoptosis inducer; EC 5.99.1.2 (DNA topoisomerase) inhibitor; prodrug	2016	2022	5.0	low	1	1
verapamil hydrochloride	1			2013	2013	11.0	low	1	0
efavirenz	1	acetylenic compound; benzoxazine; cyclopropanes; organochlorine compound; organofluorine compound	antiviral drug; HIV-1 reverse transcriptase inhibitor	2013	2013	11.0	low	1	0
epigallocatechin gallate	1	flavans; gallate ester; polyphenol	antineoplastic agent; antioxidant; apoptosis inducer; geroprotector; Hsp90 inhibitor; neuroprotective agent; plant metabolite	2020	2020	4.0	low	1	0
bendamustine	1	benzimidazoles		2013	2013	11.0	low	1	0
caroverine	1	quinoxaline derivative		2013	2013	11.0	low	1	0
cgs 9343b	1	benzimidazoles		2013	2013	11.0	low	1	0
telmisartan	1	benzimidazoles; biphenyls; carboxybiphenyl	angiotensin receptor antagonist; antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; environmental contaminant; xenobiotic	2013	2013	11.0	low	1	0
2-methoxyestradiol	1	17beta-hydroxy steroid; 3-hydroxy steroid	angiogenesis modulating agent; antimitotic; antineoplastic agent; human metabolite; metabolite; mouse metabolite	2013	2013	11.0	low	1	0
alacepril	1	dipeptide; thioacetate ester	EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor	2013	2013	11.0	low	1	0
ubenimex	1			2013	2013	11.0	low	1	0
gallocatechol	1	catechin; flavan-3,3',4',5,5',7-hexol	antioxidant; food component; plant metabolite	2020	2020	4.0	low	1	0
strictinin	1			2020	2020	4.0	low	1	0
vinpocetine	1			2013	2013	11.0	medium	1	0
6-hydroxydopa	1	non-proteinogenic alpha-amino acid		2020	2020	4.0	low	1	0
deguelin	1	aromatic ether; diether; organic heteropentacyclic compound; rotenones	angiogenesis inhibitor; anti-inflammatory agent; antineoplastic agent; antiviral agent; apoptosis inducer; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; mitochondrial NADH:ubiquinone reductase inhibitor; plant metabolite	2013	2013	11.0	low	1	0
triptolide	1	diterpenoid; epoxide; gamma-lactam; organic heteroheptacyclic compound	antispermatogenic agent; plant metabolite	2013	2013	11.0	low	1	0
sr 48692	1	N-acyl-amino acid		2013	2013	11.0	low	1	0
elacridar	1			2013	2013	11.0	low	1	0
gefitinib	1	aromatic ether; monochlorobenzenes; monofluorobenzenes; morpholines; quinazolines; secondary amino compound; tertiary amino compound	antineoplastic agent; epidermal growth factor receptor antagonist	2013	2013	11.0	low	1	0
bay x 1005	1			2013	2013	11.0	low	1	0
gyki 53655	1			2013	2013	11.0	low	1	0
ml-3000	1			2013	2013	11.0	low	1	0
cd 437	1	adamantanes; monocarboxylic acid; naphthoic acid; phenols	apoptosis inducer; retinoic acid receptor gamma agonist	2013	2013	11.0	low	1	0
docetaxel anhydrous	1	secondary alpha-hydroxy ketone; tetracyclic diterpenoid	antimalarial; antineoplastic agent; photosensitizing agent	2013	2013	11.0	low	1	0
perifosine	1	ammonium betaine; phospholipid	EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor	2013	2013	11.0	low	1	0
mk 767	1			2013	2013	11.0	low	1	0
bazedoxifene acetate	1			2013	2013	11.0	medium	1	0
canertinib	1	monochlorobenzenes; morpholines; organofluorine compound; quinazolines	antineoplastic agent; tyrosine kinase inhibitor	2013	2013	11.0	low	1	0
birb 796	1	aromatic ether; morpholines; naphthalenes; pyrazoles; ureas	EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; immunomodulator	2013	2013	11.0	low	1	0
tipifarnib	1	imidazoles; monochlorobenzenes; primary amino compound; quinolone	antineoplastic agent; apoptosis inducer; EC 2.5.1.58 (protein farnesyltransferase) inhibitor	2013	2013	11.0	low	1	0
cyc 202	1	2,6-diaminopurines	antiviral drug; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor	2013	2013	11.0	low	1	0
sb 203580	1	imidazoles; monofluorobenzenes; pyridines; sulfoxide	EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; geroprotector; Hsp90 inhibitor; neuroprotective agent	2013	2013	11.0	low	1	0
enzastaurin	1	indoles; maleimides		2013	2013	11.0	low	1	0
erlotinib	1	aromatic ether; quinazolines; secondary amino compound; terminal acetylenic compound	antineoplastic agent; epidermal growth factor receptor antagonist; protein kinase inhibitor	2013	2013	11.0	low	1	0
piboserod	1			2013	2013	11.0	low	1	0
l 163191	1			2013	2013	11.0	low	1	0
bd 1047	1	primary amine		2013	2013	11.0	low	1	0
lapatinib	1	furans; organochlorine compound; organofluorine compound; quinazolines	antineoplastic agent; tyrosine kinase inhibitor	2013	2013	11.0	low	1	0
sorafenib	1	(trifluoromethyl)benzenes; aromatic ether; monochlorobenzenes; phenylureas; pyridinecarboxamide	angiogenesis inhibitor; anticoronaviral agent; antineoplastic agent; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; ferroptosis inducer; tyrosine kinase inhibitor	2013	2013	11.0	low	1	0
lenalidomide	1	aromatic amine; dicarboximide; isoindoles; piperidones	angiogenesis inhibitor; antineoplastic agent; immunomodulator	2013	2013	11.0	low	1	0
N-[4-(3-chloro-4-fluoroanilino)-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-2-butenamide	1	aminoquinoline		2013	2013	11.0	medium	1	0
sr 142806	1			2013	2013	11.0	low	1	0
elesclomol	1	carbohydrazide; thiocarbonyl compound	antineoplastic agent; apoptosis inducer	2013	2013	11.0	low	1	0
nsc 663284	1	quinolone		2013	2013	11.0	low	1	0
bortezomib	1	amino acid amide; L-phenylalanine derivative; pyrazines	antineoplastic agent; antiprotozoal drug; protease inhibitor; proteasome inhibitor	2013	2013	11.0	low	1	0
bardoxolone methyl	1	cyclohexenones		2013	2013	11.0	low	1	0
nsc 23766	1	aminopyrimidine; aminoquinoline; primary amino compound; secondary amino compound; tertiary amino compound	antiviral agent; apoptosis inducer; EC 3.6.5.2 (small monomeric GTPase) inhibitor; muscarinic antagonist	2013	2013	11.0	low	1	0
gw 3965	1	diarylmethane		2013	2013	11.0	low	1	0
y 27632	1	aromatic amide		2013	2013	11.0	low	1	0
6-bromoindirubin-3'-oxime	1			2013	2013	11.0	low	1	0
purvalanol b	1	purvalanol	protein kinase inhibitor	2013	2013	11.0	low	1	0
y-700	1			2013	2013	11.0	low	1	0
repsox	1	pyrazolopyridine		2013	2013	11.0	low	1	0
4,4-difluoro-N-[(1S)-3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-phenylpropyl]-1-cyclohexanecarboxamide	1	tropane alkaloid		2013	2013	11.0	medium	1	0
s 1033	1	(trifluoromethyl)benzenes; imidazoles; pyridines; pyrimidines; secondary amino compound; secondary carboxamide	anticoronaviral agent; antineoplastic agent; tyrosine kinase inhibitor	2013	2013	11.0	low	1	0
mercaptopurine	1	aryl thiol; purines; thiocarbonyl compound	anticoronaviral agent; antimetabolite; antineoplastic agent	2013	2013	11.0	low	1	0
rg108	1	indolyl carboxylic acid		2013	2013	11.0	low	1	0
stf 083010	1			2013	2013	11.0	medium	1	0
N-(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-1-naphthalenecarboxamide	1	naphthalenecarboxamide		2013	2013	11.0	low	1	0
cct018159	1	benzodioxine; pyrazoles; resorcinols	antineoplastic agent; apoptosis inducer; Hsp90 inhibitor	2013	2013	11.0	low	1	0
secinh3	1	triazoles		2013	2013	11.0	low	1	0
jk184	1			2013	2013	11.0	low	1	0
tamoxifen citrate	1	citrate salt	angiogenesis inhibitor; anticoronaviral agent	2013	2013	11.0	low	1	0
hc-067047	1			2013	2013	11.0	low	1	0
bi-78d3	1	aryl sulfide		2013	2013	11.0	low	1	0
gsk 3787	1			2013	2013	11.0	low	1	0
methyl-thiohydantoin-tryptophan	1	organonitrogen compound; organooxygen compound		2013	2013	11.0	low	1	0
2-[2-chloro-6-ethoxy-4-[(3-methyl-5-oxo-1-phenyl-4-pyrazolylidene)methyl]phenoxy]acetic acid methyl ester	1	monocarboxylic acid		2013	2013	11.0	medium	1	0
4-(5-(4-methoxyphenyl)-3-phenyl-4,5-dihydro-1h-pyrazol-1-yl)benzenesulfonamide	1	sulfonamide		2013	2013	11.0	low	1	0
LSM-1318	1	oxa-steroid		2013	2013	11.0	low	1	0
rwj 67657	1			2013	2013	11.0	low	1	0
6-methyl-2-(phenylethynyl)pyridine	1	acetylenic compound; methylpyridines	anxiolytic drug; metabotropic glutamate receptor antagonist	2013	2013	11.0	low	1	0
bms 387032	1	1,3-oxazoles; 1,3-thiazoles; organic sulfide; piperidinecarboxamide; secondary carboxamide	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor	2013	2013	11.0	low	1	0
tandutinib	1	aromatic ether; N-arylpiperazine; N-carbamoylpiperazine; phenylureas; piperidines; quinazolines; tertiary amino compound	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor	2013	2013	11.0	low	1	0
vx-745	1	aryl sulfide; dichlorobenzene; difluorobenzene; pyrimidopyridazine	anti-inflammatory drug; apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor	2013	2013	11.0	low	1	0
corlanor	1	hydrochloride	cardiotonic drug	2013	2013	11.0	medium	1	0
dasatinib	1	1,3-thiazoles; aminopyrimidine; monocarboxylic acid amide; N-(2-hydroxyethyl)piperazine; N-arylpiperazine; organochlorine compound; secondary amino compound; tertiary amino compound	anticoronaviral agent; antineoplastic agent; tyrosine kinase inhibitor	2013	2013	11.0	low	1	0
zd 6474	1	aromatic ether; organobromine compound; organofluorine compound; piperidines; quinazolines; secondary amine	antineoplastic agent; tyrosine kinase inhibitor	2013	2013	11.0	low	1	0
compound 968	1	benzophenanthridine	EC 3.5.1.2 (glutaminase) inhibitor	2013	2013	11.0	low	1	0
sb-224289	1	1,2,4-oxadiazole; azaspiro compound; benzamides; organic heterotetracyclic compound	serotonergic antagonist	2013	2013	11.0	low	1	0
gw 7647	1	aryl sulfide; monocarboxylic acid; ureas	PPARalpha agonist	2013	2013	11.0	low	1	0
l 663536	1	aryl sulfide; indoles; monocarboxylic acid; monochlorobenzenes	antineoplastic agent; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; leukotriene antagonist	2013	2013	11.0	low	1	0
1-[6-(4-chlorophenyl)-5-imidazo[2,1-b]thiazolyl]-N-[(3,4-dichlorophenyl)methoxy]methanimine	1	imidazoles		2013	2013	11.0	medium	1	0
N4-ethyl-N6,1,2-trimethyl-N4-phenylpyrimidin-1-ium-4,6-diamine	1	aromatic amine; tertiary amino compound		2013	2013	11.0	medium	1	0
2-[[2-[2-(2,3-dihydro-1,4-benzodioxin-6-ylamino)-2-oxoethyl]-1-oxo-5-isoquinolinyl]oxy]propanoic acid ethyl ester	1	isoquinolines		2013	2013	11.0	low	1	0
sch 79797	1	quinazolines		2013	2013	11.0	low	1	0
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1h-imidazol-2-yl)benzamide	1	benzamides; benzodioxoles; imidazoles; pyridines	EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor	2013	2013	11.0	low	1	0
1-(4-Fluorophenyl)-3-(3-(4-fluorophenyl)-3-hydroxypropyl)-4-(4-hydroxyphenyl)azetidin-2-one	1	monobactam		2013	2013	11.0	medium	1	0
imd 0354	1	benzamides		2013	2013	11.0	low	1	0
ex 527	1	carbazoles; monocarboxylic acid amide; organochlorine compound		2013	2013	11.0	low	1	0
ku 55933	5			2016	2022	5.4	low	4	1
quercetin	1	7-hydroxyflavonol; pentahydroxyflavone	antibacterial agent; antineoplastic agent; antioxidant; Aurora kinase inhibitor; chelator; EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor; geroprotector; phytoestrogen; plant metabolite; protein kinase inhibitor; radical scavenger	2013	2013	11.0	low	1	0
genistein	1	7-hydroxyisoflavones	antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; geroprotector; human urinary metabolite; phytoestrogen; plant metabolite; tyrosine kinase inhibitor	2013	2013	11.0	low	1	0
fenretinide	1	monocarboxylic acid amide; retinoid	antineoplastic agent; antioxidant	2013	2013	11.0	low	1	0
ter 199	1			2013	2013	11.0	low	1	0
arachidonylcyclopropylamide	1			2013	2013	11.0	low	1	0
ly 320135	1	benzofurans		2013	2013	11.0	low	1	0
pd 166285	2			2013	2020	7.5	low	2	0
kn 62	1	piperazines		2013	2013	11.0	low	1	0
su 6656	1			2013	2013	11.0	low	1	0
semaxinib	1	olefinic compound; oxindoles; pyrroles	angiogenesis modulating agent; antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; vascular endothelial growth factor receptor antagonist	2013	2013	11.0	low	1	0
su 11248	1	monocarboxylic acid amide; pyrroles	angiogenesis inhibitor; antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; immunomodulator; neuroprotective agent; vascular endothelial growth factor receptor antagonist	2013	2013	11.0	low	1	0
palbociclib	1	aminopyridine; aromatic ketone; cyclopentanes; piperidines; pyridopyrimidine; secondary amino compound; tertiary amino compound	antineoplastic agent; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor	2013	2013	11.0	low	1	0
jnj-7706621	1	sulfonamide		2013	2013	11.0	low	1	0
cisplatin	1	diamminedichloroplatinum	antineoplastic agent; apoptosis inducer; cross-linking reagent; ferroptosis inducer; genotoxin; mutagen; nephrotoxin; photosensitizing agent	2013	2013	11.0	low	1	0
vx680	1	N-arylpiperazine		2013	2013	11.0	low	1	0
d 4476	1	imidazoles		2013	2013	11.0	low	1	0
cyc 116	1			2013	2013	11.0	low	1	0
bay 19-8004	1			2013	2013	11.0	low	1	0
axitinib	1	aryl sulfide; benzamides; indazoles; pyridines	antineoplastic agent; tyrosine kinase inhibitor; vascular endothelial growth factor receptor antagonist	2013	2013	11.0	low	1	0
pai 039	1	indole-3-acetic acids		2013	2013	11.0	low	1	0
gw2974	1	pyridopyrimidine		2013	2013	11.0	low	1	0
ispinesib	1	benzamides		2013	2013	11.0	low	1	0
temsirolimus	1	macrolide lactam		2013	2013	11.0	low	1	0
pd 184352	1	aminobenzoic acid		2013	2013	11.0	low	1	0
bibx 1382bs	1	substituted aniline		2013	2013	11.0	low	1	0
hdac-42	1	amidobenzoic acid		2013	2013	11.0	low	1	0
[4-[[4-(1-benzothiophen-2-yl)-2-pyrimidinyl]amino]phenyl]-[4-(1-pyrrolidinyl)-1-piperidinyl]methanone	1	benzamides; N-acylpiperidine		2013	2013	11.0	low	1	0
iniparib	1	carbonyl compound; organohalogen compound		2013	2013	11.0	low	1	0
mk 0752	1			2013	2013	11.0	low	1	0
gw 501516	1	1,3-thiazoles; aromatic ether; aryl sulfide; monocarboxylic acid; organofluorine compound	carcinogenic agent; PPARbeta/delta agonist	2013	2013	11.0	low	1	0
av 412	1			2013	2013	11.0	low	1	0
ag-041r	1			2013	2013	11.0	low	1	0
telatinib	1			2013	2013	11.0	low	1	0
cp 547632	1			2013	2013	11.0	low	1	0
spc-839	1			2013	2013	11.0	low	1	0
lenvatinib	1	aromatic amide; aromatic ether; cyclopropanes; monocarboxylic acid amide; monochlorobenzenes; phenylureas; quinolines	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; fibroblast growth factor receptor antagonist; orphan drug; vascular endothelial growth factor receptor antagonist	2013	2013	11.0	low	1	0
andarine	1	acetamides; anilide		2013	2013	11.0	low	1	0
gw843682x	1	(trifluoromethyl)benzenes		2013	2013	11.0	low	1	0
pd 0325901	1	difluorobenzene; hydroxamic acid ester; monofluorobenzenes; organoiodine compound; propane-1,2-diols; secondary amino compound	antineoplastic agent; EC 2.7.12.2 (mitogen-activated protein kinase kinase) inhibitor	2013	2013	11.0	low	1	0
midostaurin	1	benzamides; gamma-lactam; indolocarbazole; organic heterooctacyclic compound	antineoplastic agent; EC 2.7.11.13 (protein kinase C) inhibitor	2013	2013	11.0	low	1	0
ag 14361	1	benzimidazoles		2013	2013	11.0	low	1	0
sb 265610	1			2013	2013	11.0	low	1	0
fr 148083	1	aromatic ether; macrolide; phenols; secondary alcohol; secondary alpha-hydroxy ketone	antibacterial agent; antineoplastic agent; metabolite; NF-kappaB inhibitor	2013	2013	11.0	low	1	0
mocetinostat	1	aminopyrimidine; benzamides; pyridines; secondary amino compound; secondary carboxamide; substituted aniline	antineoplastic agent; apoptosis inducer; autophagy inducer; cardioprotective agent; EC 3.5.1.98 (histone deacetylase) inhibitor; hepatotoxic agent	2013	2013	11.0	low	1	0
osi 930	1	aromatic amide		2013	2013	11.0	low	1	0
ki 20227	1			2013	2013	11.0	low	1	0
scio-469	1	aromatic amide; aromatic ketone; chloroindole; dicarboxylic acid diamide; indolecarboxamide; monofluorobenzenes; N-acylpiperazine; N-alkylpiperazine	antineoplastic agent; apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor	2013	2013	11.0	low	1	0
ssr 69071	1	pyridopyrimidine		2013	2013	11.0	low	1	0
pi103	1	aromatic amine; morpholines; organic heterotricyclic compound; phenols; tertiary amino compound	antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; mTOR inhibitor	2013	2013	11.0	low	1	0
sb 210313	1			2013	2013	11.0	high	1	0
gw 4064	1	stilbenoid		2013	2013	11.0	low	1	0
sa 4503	1			2013	2013	11.0	low	1	0
ic 87114	1	6-aminopurines; biaryl; quinazolines	EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor	2013	2013	11.0	low	1	0
zibotentan	1	phenylpyridine		2013	2013	11.0	low	1	0
tivozanib	1	aromatic ether		2013	2013	11.0	low	1	0
hki 272	1	nitrile; quinolines	antineoplastic agent; tyrosine kinase inhibitor	2013	2013	11.0	low	1	0
tofacitinib	1	N-acylpiperidine; nitrile; pyrrolopyrimidine; tertiary amino compound	antirheumatic drug; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor	2013	2013	11.0	low	1	0
bibr 1532	1			2013	2013	11.0	low	1	0
n-(6-chloro-7-methoxy-9h-beta-carbolin-8-yl)-2-methylnicotinamide	1			2013	2013	11.0	low	1	0
rucaparib	1	azepinoindole; caprolactams; organofluorine compound; secondary amino compound	antineoplastic agent; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor	2013	2013	11.0	low	1	0
cediranib	1	aromatic ether		2013	2013	11.0	low	1	0
gw0742	1	monocarboxylic acid		2013	2013	11.0	low	1	0
ps1145	1	beta-carbolines		2013	2013	11.0	low	1	0
bay 41-8543	1	pyrazolopyridine		2013	2013	11.0	low	1	0
chir 99021	1	aminopyridine; aminopyrimidine; cyanopyridine; diamine; dichlorobenzene; imidazoles; secondary amino compound	EC 2.7.11.26 (tau-protein kinase) inhibitor	2013	2013	11.0	low	1	0
sb 525334	1	quinoxaline derivative		2013	2013	11.0	low	1	0
way-362450	1	indoles		2013	2013	11.0	low	1	0
masitinib	1	1,3-thiazoles; benzamides; N-alkylpiperazine; pyridines	antineoplastic agent; antirheumatic drug; tyrosine kinase inhibitor	2013	2013	11.0	low	1	0
bx795	1	ureas		2013	2013	11.0	low	1	0
pazopanib	1	aminopyrimidine; indazoles; sulfonamide	angiogenesis modulating agent; antineoplastic agent; tyrosine kinase inhibitor; vascular endothelial growth factor receptor antagonist	2013	2013	11.0	low	1	0
sepantronium	1	organic cation		2013	2013	11.0	low	1	0
azd 6244	1	benzimidazoles; bromobenzenes; hydroxamic acid ester; monochlorobenzenes; organofluorine compound; secondary amino compound	anticoronaviral agent; antineoplastic agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor	2013	2013	11.0	low	1	0
1-(2-(1-adamantyl)ethyl)-1-pentyl-3-(3-(4-pyridyl)propyl)urea	1			2013	2013	11.0	low	1	0
N-(3-cyanophenyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-carboxamide	1	1,3,4-oxadiazoles; benzamides; biphenyls; nitrile	EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor	2013	2013	11.0	medium	1	0
ar c155858	1			2013	2013	11.0	low	1	0
aee 788	1	6-{4-[(4-ethylpiperazin-1-yl)methyl]phenyl}-N-(1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; epidermal growth factor receptor antagonist; trypanocidal drug	2013	2013	11.0	low	1	0
saracatinib	1	aromatic ether; benzodioxoles; diether; N-methylpiperazine; organochlorine compound; oxanes; quinazolines; secondary amino compound	anticoronaviral agent; antineoplastic agent; apoptosis inducer; autophagy inducer; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; radiosensitizing agent	2013	2013	11.0	low	1	0
sd-208	1			2013	2013	11.0	low	1	0
vx 702	1	phenylpyridine		2013	2013	11.0	low	1	0
volasertib	1			2013	2013	11.0	low	1	0
PB28	1	aromatic ether; piperazines; tetralins	anticoronaviral agent; antineoplastic agent; apoptosis inducer; sigma-2 receptor agonist	2013	2013	11.0	low	1	0
azd 7762	1	aromatic amide; thiophenes		2013	2013	11.0	low	1	0
krp-203	1			2013	2013	11.0	low	1	0
mk 0354	1			2013	2013	11.0	low	1	0
regorafenib	1	(trifluoromethyl)benzenes; aromatic ether; monochlorobenzenes; monofluorobenzenes; phenylureas; pyridinecarboxamide	antineoplastic agent; hepatotoxic agent; tyrosine kinase inhibitor	2013	2013	11.0	low	1	0
acetic acid 2-[4-methyl-8-(4-morpholinylsulfonyl)-1,3-dioxo-2-pyrrolo[3,4-c]quinolinyl]ethyl ester	1	pyrroloquinoline		2013	2013	11.0	low	1	0
6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)-4-pyrimidinyl]amino]-2,2-dimethyl-4H-pyrido[3,2-b][1,4]oxazin-3-one	1	methoxybenzenes; substituted aniline		2013	2013	11.0	low	1	0
brivanib	1	aromatic ether; diether; fluoroindole; pyrrolotriazine; secondary alcohol	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; drug metabolite; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; fibroblast growth factor receptor antagonist	2013	2013	11.0	low	1	0
icg 001	1	peptide		2013	2013	11.0	low	1	0
mp470	1	N-arylpiperazine		2013	2013	11.0	low	1	0
nu 7441	2	dibenzothiophenes		2013	2019	8.0	low	2	0
at 7519	1	dichlorobenzene; piperidines; pyrazoles; secondary carboxamide	antineoplastic agent; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor	2013	2013	11.0	low	1	0
bi 2536	1			2013	2013	11.0	low	1	0
danusertib	1	piperazines		2013	2013	11.0	low	1	0
N-[4-(2-tert-butylphenyl)sulfonylphenyl]-2,3,4-trihydroxy-5-[(2-propan-2-ylphenyl)methyl]benzamide	1	benzamides		2013	2013	11.0	low	1	0
N-[5-[[5-[(4-acetyl-1-piperazinyl)-oxomethyl]-4-methoxy-2-methylphenyl]thio]-2-thiazolyl]-4-[(3,3-dimethylbutan-2-ylamino)methyl]benzamide	1	benzamides		2013	2013	11.0	low	1	0
abt 869	1	aromatic amine; indazoles; phenylureas	angiogenesis inhibitor; antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor	2013	2013	11.0	low	1	0
dorsomorphin	1	aromatic ether; piperidines; pyrazolopyrimidine; pyridines	bone morphogenetic protein receptor antagonist; EC 2.7.11.31 {[hydroxymethylglutaryl-CoA reductase (NADPH)] kinase} inhibitor	2013	2013	11.0	low	1	0
ac 261066	1			2013	2013	11.0	low	1	0
carfilzomib	1	epoxide; morpholines; tetrapeptide	antineoplastic agent; proteasome inhibitor	2013	2013	11.0	low	1	0
gw9508	1	aromatic amine		2013	2013	11.0	low	1	0
jnj 26854165	1			2013	2013	11.0	low	1	0
pf 573228	1	quinolines		2013	2013	11.0	low	1	0
gw 2580	1			2013	2013	11.0	low	1	0
idelalisib	1	aromatic amine; organofluorine compound; purines; quinazolines; secondary amino compound	antineoplastic agent; apoptosis inducer; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor	2013	2013	11.0	low	1	0
crizotinib	1	3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine	antineoplastic agent; biomarker; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor	2013	2013	11.0	low	1	0
5-(5,6-dimethoxy-1-benzimidazolyl)-3-[(2-methylsulfonylphenyl)methoxy]-2-thiophenecarbonitrile	1	benzimidazoles		2013	2013	11.0	low	1	0
4-[2-(2-chloro-4-fluoroanilino)-5-methyl-4-pyrimidinyl]-N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-1H-pyrrole-2-carboxamide	1	aromatic amide; heteroarene		2013	2013	11.0	low	1	0
osi 906	1	cyclobutanes; quinolines		2013	2013	11.0	low	1	0
ly2109761	1			2013	2013	11.0	low	1	0
chir-265	1	aromatic ether		2013	2013	11.0	low	1	0
motesanib	1	pyridinecarboxamide		2013	2013	11.0	low	1	0
az-628	1	benzamides		2013	2013	11.0	low	1	0
trametinib	1	acetamides; aromatic amine; cyclopropanes; organofluorine compound; organoiodine compound; pyridopyrimidine; ring assembly	anticoronaviral agent; antineoplastic agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; geroprotector	2013	2013	11.0	low	1	0
pf-562,271	1	indoles		2013	2013	11.0	low	1	0
veliparib	1	benzimidazoles	EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor	2013	2013	11.0	low	1	0
ku-0060648	1	dibenzothiophenes		2013	2013	11.0	low	1	0
dactolisib	2	imidazoquinoline; nitrile; quinolines; ring assembly; ureas	antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; mTOR inhibitor	2013	2016	9.5	low	2	0
palomid 529	1			2013	2013	11.0	low	1	0
tosedostat	1	carboxylic ester; hydroxamic acid; secondary carboxamide		2013	2013	11.0	low	1	0
mdv 3100	1	(trifluoromethyl)benzenes; benzamides; imidazolidinone; monofluorobenzenes; nitrile; thiocarbonyl compound	androgen antagonist; antineoplastic agent	2013	2013	11.0	low	1	0
ku 60019	3			2013	2022	6.0	high	2	1
gsk 461364	1	(trifluoromethyl)benzenes		2013	2013	11.0	low	1	0
n-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide	1			2013	2013	11.0	low	1	0
nvp-tae684	1	piperidines		2013	2013	11.0	low	1	0
4-methyl-3-(2-(2-morpholinoethylamino)quinazolin-6-yl)-n-(3-(trifluoromethyl)phenyl)benzamide	1			2013	2013	11.0	medium	1	0
gsk 269962a	1			2013	2013	11.0	low	1	0
a-83-01	1			2013	2013	11.0	low	1	0
3-[(1-methyl-3-indolyl)methylidene]-1H-pyrrolo[3,2-b]pyridin-2-one	1	indoles		2013	2013	11.0	medium	1	0
vx-770	1	aromatic amide; monocarboxylic acid amide; phenols; quinolone	CFTR potentiator; orphan drug	2013	2013	11.0	low	1	0
buparlisib	1	aminopyridine; aminopyrimidine; morpholines; organofluorine compound	antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor	2013	2013	11.0	low	1	0
azd 1480	1			2013	2013	11.0	low	1	0
fedratinib	1	sulfonamide		2013	2013	11.0	low	1	0
gsk690693	1	1,2,5-oxadiazole; acetylenic compound; aromatic amine; aromatic ether; imidazopyridine; piperidines; primary amino compound; tertiary alcohol	antineoplastic agent; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor	2013	2013	11.0	low	1	0
cnf 2024	1	2-aminopurines; aromatic ether; organochlorine compound; pyridines	antineoplastic agent; Hsp90 inhibitor	2013	2013	11.0	low	1	0
ku 0063794	1	benzyl alcohols; monomethoxybenzene; morpholines; pyridopyrimidine; tertiary amino compound	antineoplastic agent; mTOR inhibitor	2013	2013	11.0	low	1	0
azd 7545	1	benzamides; monochlorobenzenes; organofluorine compound; secondary carboxamide; sulfone; tertiary alcohol; tertiary carboxamide	EC 2.7.11.2 - [pyruvate dehydrogenase (acetyl-transferring)] kinase inhibitor; hypoglycemic agent	2013	2013	11.0	low	1	0
nutlin-3b	1	Nutlin; piperazinone	anticoronaviral agent	2013	2013	11.0	low	1	0
pf 04217903	1	quinolines		2013	2013	11.0	low	1	0
gdc 0941	1	indazoles; morpholines; piperazines; sulfonamide; thienopyrimidine	EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor	2013	2013	11.0	low	1	0
sm 164	1	benzenes; organic heterobicyclic compound; secondary carboxamide; triazoles	antineoplastic agent; apoptosis inducer; radiosensitizing agent	2013	2013	11.0	low	1	0
ph 797804	1	aromatic ether; benzamides; organobromine compound; organofluorine compound; pyridone	anti-inflammatory agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor	2013	2013	11.0	low	1	0
pha 408	1			2013	2013	11.0	low	1	0
gsk 1016790a	1	1-benzothiophenes; aromatic primary alcohol; dichlorobenzene; N-acylpiperazine; sulfonamide; tertiary carboxamide	TRPV4 agonist	2013	2013	11.0	low	1	0
olaparib	1	cyclopropanes; monofluorobenzenes; N-acylpiperazine; phthalazines	antineoplastic agent; apoptosis inducer; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor	2013	2013	11.0	low	1	0
srt1720	1			2013	2013	11.0	low	1	0
plx 4720	1	aromatic ketone; difluorobenzene; organochlorine compound; pyrrolopyridine; sulfonamide	antineoplastic agent; B-Raf inhibitor	2013	2013	11.0	low	1	0
cx 4945	1			2013	2013	11.0	low	1	0
cudc 101	1			2013	2013	11.0	low	1	0
mln 8237	1	benzazepine		2013	2013	11.0	low	1	0
lde225	1	aminopyridine; aromatic ether; benzamides; biphenyls; morpholines; organofluorine compound; tertiary amino compound	antineoplastic agent; Hedgehog signaling pathway inhibitor; SMO receptor antagonist	2013	2013	11.0	low	1	0
gdc 0449	1	benzamides; monochlorobenzenes; pyridines; sulfone	antineoplastic agent; Hedgehog signaling pathway inhibitor; SMO receptor antagonist; teratogenic agent	2013	2013	11.0	low	1	0
sgx 523	1	aryl sulfide; biaryl; pyrazoles; quinolines; triazolopyridazine	c-Met tyrosine kinase inhibitor; nephrotoxic agent	2013	2013	11.0	low	1	0
bms 777607	1	aromatic amide		2013	2013	11.0	low	1	0
sgi 1776	1	imidazoles		2013	2013	11.0	low	1	0
pci 32765	1	acrylamides; aromatic amine; aromatic ether; N-acylpiperidine; pyrazolopyrimidine; tertiary carboxamide	antineoplastic agent; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor	2013	2013	11.0	low	1	0
ponatinib	1	(trifluoromethyl)benzenes; acetylenic compound; benzamides; imidazopyridazine; N-methylpiperazine	antineoplastic agent; tyrosine kinase inhibitor	2013	2013	11.0	low	1	0
amg 900	1			2013	2013	11.0	low	1	0
mk-1775	2	piperazines		2013	2020	7.5	low	2	0
bag956	1			2013	2013	11.0	low	1	0
quizartinib	1	benzoimidazothiazole; isoxazoles; morpholines; phenylureas	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; necroptosis inhibitor	2013	2013	11.0	low	1	0
N-[4-[3-[[[7-(hydroxyamino)-7-oxoheptyl]amino]-oxomethyl]-5-isoxazolyl]phenyl]carbamic acid tert-butyl ester	1	carbamate ester		2013	2013	11.0	low	1	0
tak 733	1			2013	2013	11.0	low	1	0
mk 2206	1	organic heterotricyclic compound	EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor	2013	2013	11.0	low	1	0
navitoclax	1	aryl sulfide; monochlorobenzenes; morpholines; N-sulfonylcarboxamide; organofluorine compound; piperazines; secondary amino compound; sulfone; tertiary amino compound	antineoplastic agent; apoptosis inducer; B-cell lymphoma 2 inhibitor	2013	2013	11.0	low	1	0
sns 314	1	ureas		2013	2013	11.0	low	1	0
jzl 184	1	benzodioxoles		2013	2013	11.0	low	1	0
n-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide	1	aminopyrimidine; benzamides; morpholines; nitrile; secondary amino compound; tertiary amino compound	anti-anaemic agent; antineoplastic agent; apoptosis inducer; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor	2013	2013	11.0	low	1	0
dcc-2036	1	organofluorine compound; phenylureas; pyrazoles; pyridinecarboxamide; quinolines	tyrosine kinase inhibitor	2013	2013	11.0	low	1	0
cabozantinib	1	aromatic ether; dicarboxylic acid diamide; organofluorine compound; quinolines	antineoplastic agent; tyrosine kinase inhibitor	2013	2013	11.0	low	1	0
N-(2,6-difluorophenyl)-5-[3-[2-[5-ethyl-2-methoxy-4-[4-(4-methylsulfonyl-1-piperazinyl)-1-piperidinyl]anilino]-4-pyrimidinyl]-2-imidazo[1,2-a]pyridinyl]-2-methoxybenzamide	1	benzamides		2013	2013	11.0	low	1	0
incb-018424	1	nitrile; pyrazoles; pyrrolopyrimidine	antineoplastic agent; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor	2013	2013	11.0	low	1	0
bix 01294	1	piperidines		2013	2013	11.0	low	1	0
pf 3845	1	piperidines		2013	2013	11.0	low	1	0
gsk 2126458	1	aromatic ether; difluorobenzene; pyridazines; pyridines; quinolines; sulfonamide	anticoronaviral agent; antineoplastic agent; autophagy inducer; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; mTOR inhibitor; radiosensitizing agent	2013	2013	11.0	low	1	0
ixazomib	1	benzamides; boronic acids; dichlorobenzene; glycine derivative	antineoplastic agent; apoptosis inducer; drug metabolite; orphan drug; proteasome inhibitor	2013	2013	11.0	low	1	0
ldn 193189	1	pyrimidines		2013	2013	11.0	low	1	0
plx4032	1	aromatic ketone; difluorobenzene; monochlorobenzenes; pyrrolopyridine; sulfonamide	antineoplastic agent; B-Raf inhibitor	2013	2013	11.0	low	1	0
(2S)-2-[[2-(2,3-dihydro-1H-inden-5-yloxy)-9-[(4-phenylphenyl)methyl]-6-purinyl]amino]-3-phenyl-1-propanol	1	biphenyls		2013	2013	11.0	low	1	0
gsk 1363089	1	aromatic ether		2013	2013	11.0	low	1	0
kin-193	1	pyridopyrimidine		2013	2013	11.0	low	1	0
bay 869766	1			2013	2013	11.0	low	1	0
4-[6-[4-(methoxycarbonylamino)phenyl]-4-(4-morpholinyl)-1-pyrazolo[3,4-d]pyrimidinyl]-1-piperidinecarboxylic acid methyl ester	1	carbamate ester		2013	2013	11.0	low	1	0
6-[(3-aminophenyl)methyl]-4-methyl-2-methylsulfinyl-5-thieno[3,4]pyrrolo[1,3-d]pyridazinone	1	organic heterobicyclic compound; organonitrogen heterocyclic compound; organosulfur heterocyclic compound		2013	2013	11.0	low	1	0
3-[[4-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)-1,4-diazepan-1-yl]sulfonyl]aniline	1	benzenes; sulfonamide		2013	2013	11.0	low	1	0
CAY10626	1	ureas		2013	2013	11.0	medium	1	0
thiopental sodium	1	organochlorine compound; piperazines; pyrimidines	antineoplastic agent; tyrosine kinase inhibitor	2013	2013	11.0	low	1	0
pha 793887	1	piperidinecarboxamide		2013	2013	11.0	low	1	0
nvp-bsk805	1			2013	2013	11.0	low	1	0
xmd 8-92	1	pyrimidobenzodiazepine	protein kinase inhibitor	2013	2013	11.0	low	1	0
jq1 compound	1	carboxylic ester; organochlorine compound; tert-butyl ester; thienotriazolodiazepine	angiogenesis inhibitor; anti-inflammatory agent; antineoplastic agent; apoptosis inducer; bromodomain-containing protein 4 inhibitor; cardioprotective agent; ferroptosis inducer	2013	2013	11.0	low	1	0
jnj38877605	1	quinolines		2013	2013	11.0	low	1	0
N-[3-(1,3-benzothiazol-2-yl)-5,6-dihydro-4H-thieno[2,3-c]pyrrol-2-yl]acetamide	1	benzothiazoles		2013	2013	11.0	medium	1	0
dinaciclib	1	pyrazolopyrimidine		2020	2020	4.0	low	1	0
torin 1	1	N-acylpiperazine; N-arylpiperazine; organofluorine compound; pyridoquinoline; quinolines	antineoplastic agent; mTOR inhibitor	2013	2013	11.0	low	1	0
ly2940680	1			2013	2013	11.0	low	1	0
1-[4-fluoro-3-(trifluoromethyl)phenyl]-3-(5-pyridin-4-yl-1,3,4-thiadiazol-2-yl)urea	1	ureas		2013	2013	11.0	low	1	0
ro 4929097	1	dibenzoazepine; dicarboxylic acid diamide; lactam; organofluorine compound	EC 3.4.23.46 (memapsin 2) inhibitor	2013	2013	11.0	medium	1	0
gsk4112	1			2013	2013	11.0	low	1	0
torin 2	1	aminopyridine; organofluorine compound; primary amino compound; pyridoquinoline	antineoplastic agent; mTOR inhibitor	2013	2013	11.0	low	1	0
pf-4708671	1			2013	2013	11.0	low	1	0
N-[4-(1-benzoyl-4-piperidinyl)butyl]-3-(3-pyridinyl)-2-propenamide	1	benzamides; N-acylpiperidine		2013	2013	11.0	medium	1	0
2-methoxy-N-[3-[4-[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]anilino]-6-quinazolinyl]prop-2-enyl]acetamide	1	aromatic ether; methylpyridines; olefinic compound; quinazolines; secondary amino compound; secondary carboxamide; toluenes		2013	2013	11.0	medium	1	0
belinostat	1	olefinic compound		2013	2013	11.0	medium	1	0
ethyl 1-benzyl-3-hydroxy-2(5h)-oxopyrrole-4-carboxylate	1	carboxylic acid; pyrroline		2013	2013	11.0	low	1	0
a 769662	1	biphenyls		2013	2013	11.0	low	1	0
LimKi 3	1	1,3-thiazoles; dichlorobenzene; organofluorine compound; pyrazoles; secondary carboxamide	LIM kinase inhibitor	2013	2013	11.0	low	1	0
1-[4-amino-7-[3-(2-methoxyethylamino)propyl]-5-(4-methylphenyl)-6-pyrrolo[2,3-d]pyrimidinyl]-2-fluoroethanone	1	pyrroles		2013	2013	11.0	medium	1	0
2-[5-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-4-methoxy-2-pyrrolylidene]indole	1	dipyrrins		2013	2013	11.0	medium	1	0
N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]-2-propenamide	1	tryptamines		2013	2013	11.0	medium	1	0
3-[(5-tert-butyl-1H-imidazol-4-yl)methylidene]-6-(phenylmethylene)piperazine-2,5-dione	1	pyrazines		2013	2013	11.0	medium	1	0
gsk837149a	1			2013	2013	11.0	low	1	0
N-[4-(3-chloro-4-fluoroanilino)-7-[[(3S)-3-oxolanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-butenamide	1	quinazolines		2013	2013	11.0	medium	1	0
N-[4-(3-chloro-4-fluoroanilino)-7-methoxy-6-quinazolinyl]-4-(1-piperidinyl)-2-butenamide	1	quinazolines		2013	2013	11.0	medium	1	0
wnt-c59	1			2013	2013	11.0	low	1	0
5-[1-(2-hydroxyethyl)-3-pyridin-4-yl-4-pyrazolyl]-2,3-dihydroinden-1-one oxime	1	indanes		2013	2013	11.0	medium	1	0
sar405	1			2019	2019	5.0	low	1	0
THZ531	1	aminopyrimidine; enamide; indoles; N-acylpiperidine; organochlorine compound; secondary amino compound; secondary carboxamide	antineoplastic agent; apoptosis inducer; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor	2020	2020	4.0	low	1	0
chir 258	1			2013	2013	11.0	low	1	0
osi 027	1			2013	2013	11.0	low	1	0
hli 373	1			2013	2013	11.0	medium	1	0
pemetrexed	1	N-acyl-L-glutamic acid; pyrrolopyrimidine	antimetabolite; antineoplastic agent; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; EC 2.1.1.45 (thymidylate synthase) inhibitor; EC 2.1.2.2 (phosphoribosylglycinamide formyltransferase) inhibitor	2013	2013	11.0	low	1	0
sildenafil citrate	1	citrate salt	EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor; vasodilator agent	2013	2013	11.0	low	1	0
aprepitant	1	(trifluoromethyl)benzenes; cyclic acetal; morpholines; triazoles	antidepressant; antiemetic; neurokinin-1 receptor antagonist; peripheral nervous system drug; substance P receptor antagonist	2013	2013	11.0	low	1	0
xav939	1	(trifluoromethyl)benzenes; thiopyranopyrimidine	tankyrase inhibitor	2013	2013	11.0	low	1	0
2-carboxyarabinitol 1-phosphate	1			2013	2013	11.0	low	1	0
nintedanib	1			2013	2013	11.0	low	1	0
ver 52296	1	aromatic amide; isoxazoles; monocarboxylic acid amide; morpholines; resorcinols	angiogenesis inhibitor; antineoplastic agent; Hsp90 inhibitor	2013	2013	11.0	low	1	0
sb-590885	1	aromatic ether; imidazoles; ketoxime; pyridines; tertiary amino compound		2013	2013	11.0	medium	1	0
pf-477736	1			2013	2013	11.0	low	1	0
fenobam	1	ureas		2013	2013	11.0	low	1	0

Condition	Studies	First Year	Last Year	Average Age	Relationship Strength	2010's	post-2020
Akinetic-Rigid Variant of Huntington Disease	1	2019	2019	5.0	low	1	0
Ataxia Telangiectasia	1	2022	2022	2.0	low	0	1
Ataxia Telangiectasia Syndrome	1	2022	2022	2.0	low	0	1
Benign Neoplasms	2	2020	2022	3.0	medium	1	1
Congenital Zika Syndrome	1	2020	2020	4.0	low	1	0
Disease Models, Animal	2	2019	2020	4.5	medium	2	0
Experimental Neoplasms	1	2016	2016	8.0	low	1	0
Huntington Disease	1	2019	2019	5.0	low	1	0
Malaria, Falciparum	1	2014	2014	10.0	low	1	0
Neoplasms	2	2020	2022	3.0	medium	1	1
Plasmodium falciparum Malaria	1	2014	2014	10.0	low	1	0
Zika Virus Infection	1	2020	2020	4.0	low	1	0

Bioavailability (2)

Article	Year
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Molecular pharmacology, , Volume: 96, Issue:5	2019
Discovery of Novel 3-Quinoline Carboxamides as Potent, Selective, and Orally Bioavailable Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase. Journal of medicinal chemistry, , 07-14, Volume: 59, Issue:13	2016

cp 466722

Description

Cross-References

Synonyms (41)

Drug Classes (1)

Protein Targets (17)

Potency Measurements

Inhibition Measurements

Bioassays (85)

Research

Studies (17)

Study Types

Related Drugs (717)

Drugs in this Class (355)

Drugs Involved in Assays Together (375)

Related Conditions (12)

Bioavailability (2)